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INTRODUCTION 
Growth is the most characteristic feature of childhood. It also represents the best index 
of a child's well-being since so many prerequisites must be fullfilled for its harmonious 
course and such a multitude of pathological factors can interfere with it. It is not 
surprizing that careful monitoring of growth is common practice for all who are respon-
sible for the health of children. Registering abnormality of a growth pattern is relatively 
easy. Discovering the cause of the disturbance amongst the vast array of possibilities 
however, is frequently very difficult. 
Amongst the major prerequisites for normal growth we should first mention the intact-
ness of the dividing capacity of all cells and the integrity of specific functions such as e.g. 
collagen production by the chondrocytes. Equally important is the supply of nutrients: 
the availability of enough food of good quality, normal absorption, adequate transforma-
tion into elementary molecules, and normal transport into the cells. 
Disturbances in these functions, which can best be characterized as potentially rate 
limiting, represent the most frequent causes of stunted growth. 
The role of hormones is quite different since they are rate setting, and thus exert the 
overall control of growth. Their own secretion is regulated in most instances by the 
central nervous system, which-integrates stimuli of a wide variety: 'substrate' signals (such 
as glucose with respect to GH-secretion), hormone signals (e.g. feedback-regulation), 
integrated stimuli from within the body (e.g. sleep) and from the outside world ranging 
from simple visual impressions to complex ones such as emotional deprivation. Certain 
nuclei of the hypothalamus translate these integrated impulses into the synthesis and 
secretion of specific releasing hormones which reach the anterior pituitary gland through 
the portal system and stimulate the secretion of selected pituitary hormones. 
All anterior pituitary hormones are involved in the regulation of growth rate. The most 
important amongst them is growth hormone (GH). It has long been thought that GH 
exerted a direct action on the growth rate of tissues. The discovery of sulfation factor 
(SF), later termed somatomedin (SM), and Daughaday's hypothesis on its role as the 
mediator of GH's growth promoting effect, places GH in line with the other anterior 
pituitary hormones which all have their major effect through secondary hormones. If this 
hypothesis proves to be correct, SM would represent the major regulator of growth rate. 
In this thesis our own work on SM is reported and related to the progress made by others. 
The investigations of Daughaday and of Salmon leading to the discovery of somatomedin 
and of its potential importance for human pathology are summarized in chapter one. 
The results of our own and collaborative work make up chapter two. Initially we have 
addressed ourselves to the characteristics of somatomedin in human plasma (section A). 
Intrigued by the question which organ or organs are producing SM, the early localization 
of 1 2 s I growth hormone in the rat was studied (section B). 
Meanwhile, many different in vitro biological effects had been assigned to this substance. 
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This prompted a group of investigators to propose a change of the operational term 
'sulfation factor' into somatomedin (section C). 
Both from a physiological and from a practical standpoint, it seemed important to 
compare the species differences of SM with those of GH. The results of these studies are 
described in section D. 
The imprecision and laboriousness of the SM bioassay is notorious and has limited 
progress in purification as well as in biological and clinical studies. Attempts to improve 
the technique resulted in the description of our method in section E. 
Using this assay technique and in an attempt to define a model for an appraisal of 
hormone-target organ interactions in clinical conditions, a pilot study on the dose-res-
ponse relationship between GH, plasma SM and total urinary OH-proline in short children 
with varying plasma GH levels was carried out (section F). 
An extreme example of such a disturbed interaction is described in section G. It describes 
a patient similar to those first reported by Laron et al. (1966) in whom a lack of 
SM-generation is most likely to be the cause of their growth failure. The paper describes 
his responsiveness to GH-treatment and some characteristics of his GH-molecule. 
Chapter three summarizes the present status of our knowledge about somatomedin. It 
describes the problems of its measurement, what is known about its molecular charac-
teristics, its possible sources, the regulation of its synthesis, its biological actions and 
possible relationship with other 'growth factors'. 
Chapter one 
DISCOVERY OF 'SULFATION FACTOR' (SOMATOMEDIN) 
In 1957, Salmon and Daughaday reported that serum from growth hormone (GH) treated 
hypophysectomized rats stimulated in vitro chondroitin sulfate synthesis in cartilage, 
whereas growth hormone itself or serum from untreated hypophysectomized animals or 
the combination of both lacked this capacity. This growth hormone dependent biological 
activity in serum was termed sulfation factor. Their findings, which were later confirmed 
by many investigators (Almqvist, 1960: Kogut et a!., 1963 and others), introduced a 
totally new view on GH-action. Salmon and Daughaday's paper had been preceedcd by a 
series of reports leading to this breakthrough point. 
In 1949, Dziewiatkowski et al., demonstrated that 3 5 S-sodiumsulfate, when injected into 
normal young rats, was highly concentrated in the cartilage. Two years later Dziewiat-
kowski (1951) demonstrated that it was incorporated into chondroitin sulfate. Around 
this time, purification of growth hormone had reached a stage where its metabolic effects 
could be investigated. 
In 1921, Evans and Long had proven the hypothesis formulated by Harvey Cushing in 
1910, that the pituitary produces a growth stimulating substance. This was accomplished 
by producing gigantism in normal rats injected with crude extracts from beef pituitary 
glands. In 1933, Smith arrested growth in young rats by hypophysectomy and restored it 
by injection of crude pituitary extracts. The development of the tibia-assay as a sensitive 
method for measuring growth hormone activity stimulated progress in the purification of 
pituitary extracts. In 1944. Li and Evans isolated highly purified bovine growth hormone. 
Ellis, Huble and Simpson. using a similar preparation, demonstrated in 1953 that the in 
vivo incorporation of 3 5 S-sulfate into costal cartilage of young rats was drastically 
reduced after hypophysectomy and that 25 pg of growth hormone, when administered 
for three consecutive days, partially restored it. This was subsequently confirmed by 
Denko and Bergenstal ( 1955). 
Murphy, Daughaday and Hartnett (1956) systematically explored this phenomenon. They 
found the lowest in vivo uptake of 35 S-sulfate by rat cartilage eight to ten days after 
hypophysectomy. They further established that the stimulation of chondroitin sulfate 
synthesis by growth hormone was dose related: a linear log dose-response curve was 
obtained with dosages ranging from 10 to 250 11g twice daily. 
Meanwhile Layton ( 1950 a and b) had published data on the sulfate fixation in vitro in 
many tissues of mammals and chicken embryo's, and in 1952 BostrOm and M8.nsson 
described a technique for measuring in vitro 3 5 S-sulfate incorporation into calf costal 
cartilage, using Krebs' solution as incubation medium. It was essentially this technique. 
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but incubating costal cartilage from hypophysectomized rats, which Salmon and Daugh-
aday used for their first experiments with serum, mentioned above. 
They found that in vitro incorporation of 3 5 S-sulfate1 into cartilage from hypophysecto-
mized (hypox-) rats was lower than in control animals. Bovine growth hormone added in 
vitro to hypox rat serum in concentrations up to 0.14 ,ug/ml had no effect. In the absence 
of serum, the same preparation exerted only a minimal effect even at a concentration of 
50 ,ug/ml. However, when plasma from normal rats or from hypox rats, treated with 
growth hormone was used, a dose related response resulted with doubling or even tripling 
of the 3 5 S-incorporation over the controls. This GH dependent biological activity was 
called sulfation factor. 
With their in vitro assay technique Daughaday and his collaborators then started 
measuring 'sulfation factor' activity in the human (Daughaday et al., 1959; Daughaday 
and Parker, 1963). They found low values in hypopituitary patients which could be 
restored by growth hormone treatment. High values were found in acromegalies. This 
suggested an important role of 'sulfation factor' in the regulation of normal and abnormal 
growth. 
Not only the synthesis of chondroitin sulfate in cartilage but also its collagen synthesis 
(Daughaday and Mariz, 1962) and DNA-replication (Daughaday and Reeder, 1966) were 
subsequently shown to be dependent on some intermediary substance or substances 
induced by growth hormone. It was tentatively concluded that sulfation factor might be 
responsible for all these effects (Daughaday and Reeder, 1966; Daughaday and Kipnis, 
1966). 
10 
Chapter two 
STUDIES ON SOMATOMEDIN 
A. Partial characterization 
1. Partial characterization of sulfation and thymidine 
factors in acromegalic plasma. 
This study was done in collaboration with J.J. VanWyk, R.P. Weaver and H.E. Mayberry. 
It was undertaken to characterize the growth hormone dependent plasma factors which 
stimulate sulfate uptake (PSF) and thymidine incorporation (PTF) in cartilage segments 
from hypophysectomized rats. 
An assay system utilizing labeling with 3 5 S04 and 3 H~methyl-thymidine was devised to 
measure both types of activity simultaneously and to determine whether these activities 
run in parallel during chemical fractionation procedures. 
Acromegalic plasma stimulated sulfate and thymidine uptake as much as 18x and 30x 
respectively above the uptake of the basal medium. Activity measurements were not 
rigidly quantitative due to high variances, especially in PTF measurements. 
Both activities in acromegalic plasma were thermo-labile at' 80°C for 30 minutes. PSF was 
stable from pH 2 to 10. PTF was possibly partially inactivated at pH 2. Digestion with 
pronase destroyed PSF and probably PTF. Acromegalic plasma was fractionated by 
graded ethanol precipitation, ion exchange chromatography, starch gel electrophoresis, and 
molecular sieving through Sephadex (G-100, G-200). PSF and PTF activities run in 
parallel throughout these procedures. These findings suggest that the active material is 
associated with a peptide with a molecular weight between 9500 and 35000, which is 
more positively charged than many other plasma proteins. 
Experimental details are described in paper 1, which is reprinted in the addendum. 
2. Further purification and characterization of sul[ation factor and thymidine 
factor from acromegalic plasma. 
In a collaborative effort with J.J. Van Wyk, K. Hall and R.P. Weaver, sulfation factor 
(PSF) and thymidine factor (PTF) were further chemically characterized in whole 
acromegalic plasma and were also studied in acid ethanol (AE) extracts of plasma. In 
whole plasma PSF and PTF are excluded by the XM-100 ultrafiltration membrane and 
behave as large proteins. After extraction with acid ethanol the molecular weight 
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appeared to be> 3,900 < 12,400, suggesting that in native plasma PSF and PTF are either 
aggregated or bound to a larger carrier protein. 
Two species of peptides with PSF and PTF activity were found. Chromatography of 
whole plasma on DEAE-cellulose revealed a major peak of biologic activity which was not 
adsorbed at pH 8.5 and a smaller component which was adsorbed at pH 8.5 but eluted at 
pH 5.5. Electrofocusing of AE extracts revealed a sharp minor peak at pH 5.2 and a 
broader major peak at pH 6.6-6.7. The possibility that the more acidic component may 
be due to insulin cannot be excluded. HV electrophoresis of a purified AE extract 
revealed activity only in the neutral zone. Chromatography of an AE extract on CMC-
cellulose at pH 5.6 in a linear ionic gradient between 0.01 and 0.40 M resulted in the 
recovery of PSF and PTF in a small protein peak well separated from the bulk of other 
proteins. 
Rechromatography of the CMC eluate on Sephadex G-50 yielded a preparation with an 
increase in specific activity over native plasma of 6,200xfor PSF and l5,000x for PTF. 
This discrepancy probably reflects the removal of inhibitors having a greater effect on 
thymidine incorporation, since no separation of PSF from PTF was observed in any 
system. If a provisional molecular weight of 8,000is assumed and no allowance is made 
for residual contaminants, the purest preparation is highly active at 3.1 x 10_8. molar 
concentration. 
Paper 2 in the addendum describes the experimental details. 
B. Early localization of 12 5 !-labeled human growth hormone in adrenals 
and other organs of immature hypophysectomized rats. 
These studies were done in collaboration with H.E.Mayberry,J.J.V anWyk and W.J.Waddell. 
Since labeled hormones tend to concentrate very quickly in their respective target tissues 
after administration, human growth hormone (HGH) labeled with 125 I was injected 
intravenously into hypophysectomized, immature rats. It was hoped that early binding of 
the hormone might reveal possible sources of somatomedin production. One rat was 
frozen 6 min and another 20 min after injection by immersion in hexane cooled with dry 
ice. Whole-body sections were made of the frozen rats and autoradiograms were prepared 
by placing these sections on x-ray film. The autoradiograms revealed that, at both time 
intervals after injection, there was a high concentration of radioactive material in the 
kidney, liver and adrenal cortex. The only other tissues found to have a higher radioactive 
density than that of blood were the submandibular glands, nasal mucosa, gastric mucosa, 
bone and follicles of vibrissae. The radioactivity in the adrenal cortex was slightly higher 
in the zona glomerulosa than in the zona fasciculata and it was lowest in the zona 
reticularis. The concentration in the epiphyseal plates was no higher than that in bone or 
soft tissues. The radioactivity in the submandibular gland had'the electrophoretic mobili-
ty of growth hormone and not free iodide. The distribution in 8 organs of 1 31 I-albumin 
was compared with that of 125 1-HGH at 6 and 20 min by removal of the organs and 
direct isotope counting. The distributions substantiated the specific localizations of HGH 
seen in the autoradiograms. Pretreatment of the rats with HGH 6 min before administe-
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ring the 125 1-HGH diminished the concentration of 12 5 !-HGH in liver, adrenals and to a 
minor extent in the submandibular glands, suggesting specific binding. It was concluded 
that these organs should be focused on in subsequent studies aimed at disclosing the 
source of somatomedin. 
The experimental protocol, results and a detailed discussion are given in paper 3 of the 
addendum. 
C. Somatomedin: Proposed designation for su/fation factor 
Since the operational terms sulfation factor or thymidine factor did not adequately cover 
its apparent role, 'Somatomedin' was suggested by W.H. Daughaday, K. Hall, M.S. Raben, 
W.D. Salmon, J.J. Van Wyk and myself as an alternative designation of the growth 
hormone dependent substance mediating its effect (for detailed motivation, see paper 4 
of the addendum). 
D. An improved technique for measuring somatomedin activity in vitro* 
All current techniques for the measurement of somatomedin are based on its stimulatory 
effect on the incorporation of 3 5 S*sulfate into chondroitine-sulfate and/ or 3 H-methyl 
Thymidine into DNA of cartilage. They differ mainly by the origin of the tissue used and 
by the incubation schedules. As a consequence of this, each of the techniques has 
somewhat different characteristics which are summarized in Table 1 (Salmon & Daugha-
day 1957; Daughaday & Reeder 1966; Almqvist !961; Yde 1968; Fujisawa !964 and Hall 
1970). 
The development of the technique to be described was aimed at improving the precision 
and at diminishing laboriousness which are the two main disadvantages of the techniques 
currently in use. 
METHOD 
1. Procedure 
a. Preparation of the tissue 
The tissu~ is obtained from approximately one hundred day old pigs. A small portion of 
the thoracic cage containing the cartilagenous section of the lowest sternal rib is removed 
in the slaughterhouse shortly after the animal has been killed. The tissue is placed in 
ice-chilled isotonic saline solution and processed within two hours. After removal of most 
of the muscle, the cartilagenous portion of a single rib is sliced in transverse sections of 
2 mm thickness using a commercial meatslicer. Cylindrical tissue fragments are punched 
* These studies were done in collaboration with M.V.L. Du Caju and will appear in Ada endocrinolo-
gica, Kbh. 
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TABLE I 
Survey of the cu"ent somatomedin assay techniques 
Authors Animal Organ Isotope Precision Range* 
Salmon and hypophysect. costal 35 S (S04 ) ± 0.26 2.5-17% 
Daughaday (1957) rat cartil. 
Daughaday and 'H (Thym.) 2-17% 
Reeder ( 1966) 
Almqvist (1961) 35 S (S04) 0.14** 5-20% 
Yde (1968) normal rat 0.20 5-15% 
Fujisawa (1964) hypophysect. 5-40% 
puppies 
Hall (1970) chick pelvic 0.20 5-60% 
embryo rudiments 
Van den Brande pig costal 3sS(S04) . 0.15(n=57) 5.6 or 11.3-45.2% 
and Du Caju car til. 'H (Thym.) 0.19(n=43) 5.6-45.2% 
* Range: Concentrations (v/v) of normal human plasma yielding the linear portion of the dose response 
curve. 
** Obtained after rejecting otherwise non-valid assays. 
using either small drills or a specially designed apparatus (Fig. 1). Care is taken to keep a·· 
constant distance from the border of the slice (Fig. 2). 
b. Preincubation in saline 
The cartilage cylinders are placed in a beaker containing enriched Krebs-phosphosaline 
buffer (KPS) as described by Daughaday and Reeder (1966), and are incubated in an oven 
at 37°C for 24 hours without shaking. 
c. Incubation in test solution is done in a rack consisting of a Teflon® (Dupont)-
block with 90 holes (6 rows of 15) in which either glass tubes with tightly fitting 
punctured flat Teflon bottomplates or Teflon tubes with a similar punctured bottom, are 
lowered. The top rim of the tubes rests in a perspex plate which allows for simultaneous 
removal and processing of the tissue containing tubes. The whole rack is covered with a 
perspex roof (Fig. 3). After the tubes have been inserted into the holes, 1.0 ml of each of 
a series of dilutions of standard or unknown with KPS is dispensed in three adjacent 
tubes. Two tissue fragments are placed in each tube. The rack is covered with a perspex 
roof(Fig. 3) and is put into an incubator at 37°C for 46 hours. 
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PUNCHING APPARATUS 
SIDE VIEW 
Fig. I 
This apparatus punches cylindrical tissue fragments from a transverse section of the rib cartilage. 
Rotation of the top lever (A), pushes a sharp metal cylinder downwards through the tissue (B). While 
the lever is returned, an inner shaft remains down pushing the tissue outside of the cylinder into a 
small removable container (C). The whole procedure is done in normal saline solution. 
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Fi~. 2 
This figure shows some transverse sections of the rib after the cylinders have been punched out. It 
demonstrates the attempt to keep a rather constant distance from the perichondrium. 
d. Postincubation in isotopes 
The perspex cover plate with the tubes, containing the cartilage, is next removed from the 
block. It is lowered into a waterbath such that the lower half of the tubes is immersed in 
order to remove most of the testsolution. Next it is placed in a flat container filled with 
enriched Krebs-phosphosaline buffer containing 2 !-LCi/ml of 35 S-sulfate (carrier free) and 
3 1-l-methyl thymidine (specific activity> 10 Ci/mMol) obtained from Amersham Ltd., 
England. Again only the lower portion of the tubes is below the fluid level, exposing the 
cartilage to the isotopes. The incubation is then continued for another three hours at 
37°C. 
e. Processing the cartilage for counting 
The plate with tubes is next transferred to a container filled with water at 80°C. After 
5 minutes, washing with running tap water is started. The level of the water is forced into 
an up and down movement by a sifoning device (Fig. 4). The tissue fragments are then 
transferred into counting vials to which 0.5 ml of formic acid is added. 
They are covered with marbles and placed in a waterbath at 75°C for 30 minutes. 
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Thereafter, 10 ml of lnstagel (Packard) is added and the radioactivity is counted in a 
liquidscintillation counter. 
f. Computation of the results is done on a Hewlett-Packard 9100B desk calculator. 
After the necessary log-transformations (see below) each dose response curve is plotted, 
the linear portion is visually selected and statistically checked for validity. Regression 
analysis is done and the index of precision (5/b) is computed. The standard and the 
unknown are analyzed with respect to linearity, preparation differences, regression, 
paralellism and heteroscedasticity. Finney's g is calculated and finally the potency ratio 
with 95 or 97.5% fiducial limits is obtained. The mathematical formulae are according to 
Finney (1952). 
2. Discussion of some procedural aspects 
a. Choice of the tissue 
Before the pig cartilage was selected, other tissues had been tried. Monkey rib cartilage 
was satisfactory and was utilized in some studies on purification (same chapter, section-
A) and some in clinical studies (same chapter, section G). When this tissue was used, the 
technique was somewhat different since total transverse sections through the ribs were 
incubated, preincubation was not yet done, and the radioactive isotopes were added 
during the last 24 hours of the incubation in plasma in stead of during a postincubation 
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as described earlier. The best results, however, were obtained with cartilage from pig ribs. 
Moreover, since this tissue has the advantage of being available at no cost in large quantities 
and since dissection is easy •. it was selected for further use. 
Fig. 4 
Container for boiling and washing of the tissue after finishing the incubation. The container has a 
sifoning outlet so as to force the water into an up and down movement. 
b. Incubation schedule 
Studies by Daughaday et al.( 1968) on normal rat rib cartilage have shown that preincuba-
tion for 24 hours lowers the endogenous chondroitine-sulfate synthesis to the level 
obtained with cartilage from hypophysectomized animals. Since responses to stimulation. 
with active serum might be increased by this procedure, different preincubation periods 
with pig rib cartilage were tried. The best results were obtained with 24 hours of 
preincubation. In these experiments the preincubation was followed by 48 hours of 
incubation in the presence of plasma, the last 24 hours of which with addition of 
radioisotopes. This scheme has been followed until recently. On a suggestion by Dr. 
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W.D. Salmon, the postincubation schedule has since been introduced. From the many 
schedules tried, incubation in the testsubstance for 46 hours followed by a 3 hours 
exposure to radioisotopes, after removal of the test substance, yielded the best results. 
This diminishes the laboriousness of the procedure. The shallowness of the slope is 
adequately compensated for by the decrease of the variance, as can be concluded from 
the unchanged index of precision (Fig. 5). 
dpm35s cart. 103x30 /A .p, .. R180 /A R191 103x25 R193 j;,A 25 y 
5 125 
10 ! 
5 (/' 25 /I' d 5 25 //' .... ->S t25 II f ,/ 1 ,.,. .... .5 .62 1.25 
L 
....... 
. 625 I ..... 
"' I I I 55 11.3 225 45.2% 5.6 22B 805% 5.6 225 90.5%[v/v] 
Fig. 5 
In this experiment the standard curves obtained for 3 5 S-up take after different incubation schedules 
are shown. 
A: 24 hrs. preincubation in KPS, 48 hrs. incubation with the testsubstance, the last 24 hrs. of which in 
the presence of the isotopes. 
B: 24 hrs. preincubation in KPS, 46 hrs. of incubation in the testsubstance and 3 hrs. postincubation 
in KPS +isotopes. 
Indices of precision for both 3 5 S-uptake and 3 H-Thymidine incorporation: 
"S 'H 
A B A B 
R 180 0.09 0.14 0.17 0.13 
R 191 0.13 0.08 0.17 0.11 
R 193 0.22 0.14 0.13 0.21 
c. Washing 
Washing the tissue with running tap water efficiently removes non incorporated Naz-
3 5 S04 and 3 H*Thymidine. After only a few minutes, residual counts are reduced to a 
minimal and constant level. 30 Minutes was selected as a suitable washing period. 
d. Drying and weighing 
Before the dissection of the cartilage had been rigorously standardized, it was necessary 
to express the results as a function of tissue mass. It was found that after drying by 
exposure to ambient air, a stable weight was obtained after a few hours. This technique 
has been used until the incubat~on rack was introduced. Since drying appeared not to be 
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fast enough when the tissue was left in the tubes, an additional one hour of drying in the 
oven at 60°C was added which gave satisfactory results. 
Introduction of the punching apparatus, however, has reduced the variation of the tissue 
fragments to an extent where the omission of weighing no longer importantly affects the 
index of precision (average s;b, weighing versus not weighing, 35 S-uptake: 0.167 vs 0.161; 
n = !6, 3 H-uptake: 0.169 vs 0.166; n = 17). 
This results in a significant reduction of the amount of work involved since not only 
drying and weighing can be omitted but the punch-taped counting data can be directly 
read into the calculator. 
e. Standard 
Heparinized plasma from 5 healthy adult volunteers was pooled and separated in 5 ml 
aliquots in order to avoid repeated freezing and thawing. The samples are stored at 
-70'C. 
3. Sulfate pool 
The sulfate concentration in the incubation medium is 1.162 mMol/L. In plasma it is 
0.303 mMol/L on the average (Sturm & Pothmann 1940). Since a wide range of 
concentrations is being used this results in important changes of the sulfate pool. When a 
constant amount of 3 5 S is added to this mixture, as is customary in all current techniques 
and as we also did until postincubation was introduced, one can anticipate a simple 
TABLE 2 
Log dpm 3 5 S as a function of log S04 -pool at different plasrnaconcentrations. 
Plasma Slope ,uMol sulfatc/ml Correction factor towards 
concentration usually present constant S04 -pool 
(o/r.) Exp. I 2 3 average in the assay (0.303 "Mol/ml) 
2.8 0.57 0.63 0.42 0.54 1.165 2.92 
5.6 0.57 0.58 0.52 0.56 1.141 2.94 
11.3 0.59 0.49 0.62 0.57 1.092 2.82 
22.6 0.73 0.53 0.73 0.66 0.995 2.86 
45.2 0.60 0.97 0.78 0.803 2.45 
90.5 0.96 0.81 0.84 0.87 0.411 1.24 
The sulfate pool of the incubation medium was varied between 0.3 and 2.4 ,uMol/ml for each of the 
current plasmaconcentrations used in the assay. A constant amount of 3 > S0 4 was added during the 
last 24 hours of a 48 hours-incubation. Regression analysis was done on the change of log dpm as a func-
tion of log S04 for each plasma concentration. Only curves with statistically valid criteria for linearity 
were included (97 .5% confidence limit). 
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inverse relationship between sulfate-pool and 3 5 S-incorporated for any given amount of 
biological activity. 
Experiments to document this, showed however, that the slope of log dpm as a function 
oflog sulfate pool, was less steep than -1.00 in all instances. It varied between -0.54 and 
-0.87, and was well correlated with the plasma concentration (Table 2). Knowing the 
slope for each plasma concentration in the assay, a factor could be calculated correcting 
the dpm 3 5 S for differences in sulfate pool. These correction factors towards a constant 
pool of 0.303 ,uMol are represented in Table 2, and appeared to be constant up to a 
plasma concentration of 22.6% and deviated only slightly at 45.2%. In practice therefore, 
correction is not necessary up to 45% of plasma. The linearity of the standardcurve up to 
45% in the postincubation experiments (Fig. 5) supports this conclusion. Although we 
have not done this as yet one could consider lowering the concentration of sulfate in the 
incubation medium to 0.3 mMol/L. When purified fractions are measured in which the 
sulfate concentration is totally unknown, sulfate should be removed or determined prior 
to testing. 
RESULTS 
1. Shape of the dose-response curves. Transformations 
Since all tissue for one assay is derived from a single animal, interassay variation is 
intrinsic to the method. Semi-log transformation yields a linear section in the 3 H-Thymi-
dine-uptake curve. For 3 5 S-sulfate-incorporation a log-log transformation is necessary. 
2. Sensitivity 
The utilizable portion of the dose-response curve starts at a 5.6 or 11.3%" concentration of 
our normal adult plasma pool, apparently depending on variation of the sensitivity 
amongst animals, when 3 5 S-uptake is computed, and more regularly at 5.6% for 
3 H-Thymidine-uptake. The curve is usually linear up to 45.2%. The sensitivity is less than 
with the methods using rib cartilage from hypophysectomized rats but is comparable to 
the other current techniques (Table 1). 
3. Precision 
The precision of the assay satisfies the criteria for a quantitative assay (in most cases Sjb 
~ 0.2) for 3 5 S-sulfate incorporation, but remains less satisfactory for 3 H-Thymidine-
incorporation. Average Sjb values obtained in a series of subsequent assays on plasma, 
without rejection of any, except if the upper doses of the curve did not reach the lower 
limits of the standard, were: 0,146 (n= 57) for 35 S-uptake, and 0,192 (n= 43) for 
. 
3 H-Thymidine uptake. 
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4. Specificity 
Many substances are known to influence the rate of chondroitin sulfate synthesis and 
DNA-replication of cartilage. As any other assay using these indices, the technique 
described can be anticipated not to be specific for growth hormone dependent somatome-
din. However, when the amount of endogenous or exogenous growth hormone is the only 
variable, the change in activity of the plasma reflects accurately and only the growth 
hormone dependent changes. This can be concluded from the results obtained when 
plasma of a hypopituitary patient before treatment was mixed with that during treatment 
with exogenous growth hormone. Indeed, the usual incubation with increasing plasma-
concentrations gave the following potency ratio's and 97.5% confidence limits. Before 
treatment: 0.27 (0.22- 0.34), mixed in equal portions before and on treatment: 0.41 
(0.37- 0.53), on treatment: 0.55 (0.43- 0.72). The data also allowed for comparison of 
the slopes when increasing biological activity was plotted with and without changing the 
plasma concentration (Fig. 6). No deviation from paralellism could be demonstrated. This 
suggests that only growth hormone dependent changes are reflected by the slope ob-
tained. 
ptasma concentration 
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Fig. 6 
A. Shows the regular curve obtained with plasma of a hypopituitary patient on treatment with human 
growth hormone. The data are expressed as mU by comparison with a normal standard, the content of 
which is 1 U/ml by definition. The solid line represents the calculated curve. 
B. shows the curves obtained when less and more active plasma is mixed so as to keep the total 
amount of plasma constant but to increase the biological activity (dotted lines). For comparison the 
curve obtained in A is repeated (solid line). Here again the data are expressed as mU of biological 
activity. No non-paralellism can be demonstrated. 
CONCLUSIONS 
The assay technique described seems to have the following advantages: 
I. It possesses an increased precision over the presently used methods. 
2. The utilization of porcine cartilage and of special dissection and incubation apparatus 
has diminished laboriousness. 
3. The costs have been diminished. 
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The disadvantages of the technique are: 
1. It is less sensitive than the hypophysectomized rat assay. 
2. The assay takes three days before the results are known. This is one day longer than 
the chick-embryo assay. 
The method has the disadvantage of all present techniques: it measures overall stimulato-
ry activity on chondroitine sulfate synthesis and/or DNA replication and lacks specificity. 
This necessitates well controlled experimental conditions for conclusions with respect to 
growth hormone dependent somatomedin levels. The future development of a specific 
receptor assay and/or a radio-immuno assay should by-pass this problem and render the 
biological assay even more valuable in the study of non growth hormone dependent 
growth disturbances. 
SUMMARY 
A method for measuring somatomedin activity in vitro is described. Porcine costal 
cartilage fragments are prepared and incubated using special dissection and incubation 
apparatus. The schedule consists of 24 hrs preincubation, 46 hrs of incubation with the 
test substance and 3 Ius of postincubation in medium containing both 35 S-Na2 S04 and 
3 H-Thymidine. The average index of precision is 0.15 for 35 S-uptake and 0.19 for 
3 H-Thymidine. Although the assay is less sensitive than the hypophysectomized rat assay, 
it yields a considerable increase in precision, it is far less laborious to perform and is not 
so expensive. 
E. Studies on plasma somatomedin activity in different animal species* 
Growth hormone influences the growth of cartilage (and possibly other tissues) by 
stimulating the production of somatomedin (SM) which in turn transmits the somatotro-
pic effect onto the target tissue (Daughaday & Reeder 1966). ln this respect. somatome-
din bears the same relationship to growth hormone that thyroxine and the steroid 
hormones bear to their respective trophic hormones. Growth hormone possesses a much 
higher degree of species specificity than do the other pituitary hormones (Knobil and 
Greep 1959), but it is not known whether this is due to specificity in the ability to 
stimulate somatomedin production or to species specificity of the somatomedin pro-
duced. The present studies were undertaken to determine the nature of responses of rat, 
pig, monkey and human cartilage to the somatomedin-like activity in the plasma of a 
wide range of species. 
Materials and Methods 
Blood was obtained by venapuncture, collected in heparinized vessels and immediately 
* This study was done in collaboration with F. Kootte, R. Tielenburg, M. van der Wilk and T. Huyser 
and will appear in Acta endocrinologica, Kbh. 
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cooled in an icewater bath. The plasma was separated by centrifugation and stored at 
-20°C until assayed. In the earlier experiments plasma from a single animal was tested, 
whereas pools from up to 5 animals were tested in later studies. All blood was obtained 
from adult animals, except for the rats and the dog, which prepubertal. In the text and 
the figures some of the common names used need further specification: 
Monkey plasma was from the Rhesus Mulatta Macacca, rat plasma from Wistar rats, the 
turtle plasma from the Testudo Hermanni, pigeon plasma from the domesticated form of 
Columba Livia and the fish plasma was from the Cyprinus Carpio. 
The bioassay was essentially as described by Daughaday and Reeder (1966) with modifi-
cations (Same chapter, sections A 1 and D). Additional variations amongst experiments 
concern the origin of the cartilage and the number of tissue fragments incubated per 
dosage of plasma. 
Monkey costal cartilage was obtained from a single male prepubertal Rhesus Mulatta 
Macacca per assay. The fragments incubated were transverse sections through the rib 
(average weight: 0.86 mg). 
Human cartilage was obtained from a female newborn presenting with duplication of the 
lower half of the body. Surgical correction was performed on the ninth day of life. 
Fragments of articular cartilage (average weight: 0.76 mg) were obtained from the knees 
and the ankle joints. 
Rat costal cartilage was obtained from normal male Wistar rats 25 days of age using the 
same technique as described earlier. (Average weight of the cartilage fragments: 1.64 mg). 
Plasma samples were serially diluted in incubation medium to the appropriate concentra-
tions and 1 ml was added to each of the replicate tubes. 
Incubations of monkey rib, and human articular cartilage were carried out with three 
fragments of cartilage in each of three tubes, whereas one rib cartilage segment from each 
of six rats was incubated in an individual tube. After 24 hrs. of incubation in the presence 
of the test-substance, one ,uCi of both 3 H-methyl-Thymidine and 35 S-Na2 S04 were added 
to each incubationflask and the incubation was continued for another 24 hrs. Further 
assay conditions were left unchanged. Assays with porcine rib cartilage were entirely as 
described earlier (same chapter, section D). The variance of 3 H-methyl-Thymidine was 
too large to allow for conclusions, and hence only 3 5 S-Na2 S04 results will be discussed. 
RESULTS 
Monkey cartilage. Steep dose-response curves were obtained with plasma from monkey, 
horse, pig, cow and dog. The slope of the curve obtained with turtle plasma was less steep 
but not significantly different from the others. Within the dosage range 3-30% (v/v), 
neither pigeon nor fish plasma were stimulatory (Fig. 7). Because of the suggestion of 
activity in the pigeon plasma, another study was carried out using plasma from a different 
animal. Again some stimulation was observed at a very low concentration, but the plasma 
rapidly became inhibitory, beginning at a concentration of 1%. 
Human cartilage (Fig. 8). The general pattern is similar to the one obtained with monkey 
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Fig. 7 
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Fragments of monkey costal cartilage were incubated in the presence of increasing concentrations of 
heparinized plasma from monkey, dog, horse, pig, cow, turtle, fish and pigeon. 
Results arc plotted on a log/log scale. Each point represents the mean of triplicate determinations. 
cartilage. The highest average values were obtained with plasma from an acromegalic, 
monkey and pig. Highly significant responses were also obtained with cow and calf 
plasma. 
Rat cartilage. This type of cartilage yielded responses with such variation amongst 
replicates, that only examination for a general trend was possible. Rat, horse and cow 
plasma gave steep dose-response curves. The turtle and fish plasma were not stimulatory, 
and pigeon plasma was very inhibitory. 
Porcirie rib cartilage. Since this assay technique possesses a greater precision, pooled 
plasma from man (n:S), pig (n:3) and cow (n:S) was tested in order to obtain more 
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Human nlftilag-c incubated in the presence of increasing concentrations of heparinized plasma from an 
acromegalic,from monkey, pig, dog, cow, rat, calf, fish and pigeon. 
Results arc plotted on a log/log scale. Each point represents the mean of triplicate determinations. 
detailed information on possible differences in slope and relative potency (Fig. 3). 
No significant differences in slope were demonstrated but the relative potencies were very 
dissimilar. 
DISCUSSION 
The data presented suggest that cartilage from man, monkey, pig and rat is capable of 
responding to the plasma somatomedin activity present in the blood of all mammals 
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tested. It cannon be concluded whether the response obtained with turtle plasma differs 
from that obtained with mammalian plasmas. Pigeon and fish definitely distinguish 
themselves from mammalian plasma since they were either inactive or inhibitory. Experi-
ments in hypophysectomized rats have shown that pretreatment with GH is necessary for 
any SM-activity to be demonstrable (Salmon and Daughaday, 1957). If this holds true for 
other species, it would be fair to conclude that the specificity with respect to the 
responsiveness to GH from different species should be located at the level of SM-genera-
tion and not at the level of SM-effect. Since the SM-assay is highly sensitive to inhibition 
by interfering substances, the possibility must be considered that differences amongst spe-
cies is more an expression of differences in inhibiting substances than in the nature and 
amount of somatome din-like activity. 
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Plasma from pigs (n = 3), and cows (n = 5) compared to a normal human plasma pool (n = 5) in the pig 
rib assay. Note the paralellism of the linear portion of the dose response curves. Vast potency 
differences CPR) are also apparent. 
Moreover, the observation that plasma from different species induces similar responses 
does not eliminate the possibility of qualitative differences in the active substance. Such 
differences are also suggested by studies of Liberti (1970) and ourselves (same chapter, 
section A2), since quite different results were obtained with regards to the behaviour of 
bovine SM and human SM on ultrafiltration membranes. 
Studies on the chemical characteristics of pig plasma with respect to SM are being conducted 
both to obtain more information on this problem and in order to investigate its suitability 
for large scale preparation of SM. 
SUMMARY 
Since responses to growth hormone (GH) have a well-defined species specificity, these 
studies were undertaken to determine whether responses to somatomedin exhibit similar 
specificity. Heparinized plasma from 10 different species ranging from fish to man was 
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accordingly assayed for somatomedin·like activity in rat, pig, monkey and human carti· 
lage. The magnitude of 3 s S04 -uptake was assessed by previously described methods and 
the paralellity of the curves compared. 
A stimulatory effect was obtained with plasma from man, monkey, pig, horse, cow, dog, 
rat and possibly turtle, whereas pigeon and fish plasma had either no effect or was 
inhibitory. Although some species differences with respect to slope and magnitude of 
response were observed, it was concluded that inter~species responses to somatomedin are 
far less restricted than inter~species responses to growth hormone. This suggests that unless 
the overall somatornedin~like activity measured in this assay can be attributed to substances 
which are quantitatively and/or qualitatively different in the various species, the species 
specificity of growth hormone exists at the level of somatomedin induction rather than in 
specificity of the somatomedin produced. 
The responsiveness of human cartilage to somatomedin from a series of other mammals 
opens up practical possibilities for large scale preparation of this hormone from non-
human sources. 
F. Dose-response relationship between growth hormone, plasma somatomedin and 
total urinary hydroxyproline excretion. A pilot study* 
Detailed information on the dose-response relationship between growth hormone (GH) 
and indices of its effects in children is not available. If the characteristics of such 
relationships were known, assessment of the hormone-target orga~ interaction in the 
many clinical conditions where a quantitative or qualitative abnormality of this inter~ 
action is suspected might become possible. Examples of such conditions are partial 
growth hormone deficiency, the large group of small children with either normal physical 
appearance or congenital malformations, obesity, malnutrition etc. The present pilot 
study was aimed at testing the possibilities of such an approach. 
Patients, materials and methods 
Six children were selected for the study. Their diagnostic data are summarized in Table 3. 
Patients Dl and D2 ,;re siblings with isolated GH deficiency. PI and P2 could not be 
classified since their plasma GH was limited but not absent on stimulation** (maximal 
levels: 9 and l 0 11U JS' IRP/ml respectively, as compared to an average of 36.8, range 14 
to 75, in twenty children with no apparent endocrine disorder). From their clinical 
appearance, skeletal age and normal plasma GH levels, Nl and N2 were considered normal 
delayed children. None of the patients had any physical abnormalities except for their 
short stature, and they had received no treatment prior to the study. They were 
hospitalized and placed on a collagenfree and calorie-constant diet. After one week of 
equilibration, the studies were started. 
* These studies were done in collaboration with M.V.L. Du Caju, C.M. Hoogerbrugge, A.M. van Male, 
J.K. Schouwstra and T. Zurcher. 
** Patiens Pl and P2 were kindly referred for this study by Dr. R. Steendijk and Prof. J.J. van der 
Werff-Ten Bosch. 
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In an attempt to reach a plateau of maximal response to each dose of human growth 
hormone (HGH) from which the patients could move to a higher level on the next dose, 
they were given a constant amount of HGH for consecutive periods of 5 days in P2 and 7 
TABLE 3 
Summary of diagnostic data 
Patient Sex Age Skeletal age Height Maximal plasma 
yearsmonths yearsmonths (SD) Growth Hormone 
Dl M 12' 4' - 9.1 <0.5 
D2 F 6' I' - 9.5 <0.5 
PI F 14' 9' -4.3 9 
P2 M 10' 9' - 3.7 10 
Nl M 7' 5' - 3.2 31 
N2 M 5" 4' - 2.6 45 
Skeletal age was assessed using the Greulich and Pyle atlas (1959). 
Height is expressed as the number of standard deviations separating the patient from the mean. 
Plasma growth hormone, measured by a charcoal-dextran method (Schopman and Hackcng, 1971) is 
expressed in pU 1st IRP per ml. The patients were tested either by insulin induced hypoglycemia (P2), 
arginine infusion test (Dl, D2, Nl, N2) or both (Pl). All had normal plasma thyroxine levels. 
days in all other children. The doses used were 0, 2, 4 and 8 mg/m 2 /day.* The biological 
potency of this GH preparation is not known, which limits the conclusions to the 
comparison of differences between individual patients. Growth hormone was adminis-
tered I.M. at 8 p.m. Day 1 of each study period is defined as the day following the first 
injection. Urine was collected throughout the study. Venous blood was drawn at 8.15 
a.m. before breakfast on day 4, and the plasma was stored at --20°C until assayed for 
somatomedin activity (SM). Creatinine was measured using a routine technique (Fawcett 
and Scott, 1960). Total urinary hydroxyproline was measured with the Hypronosticon-
test® (Organon) (Goverde and Veenkamp, 1972). Plasma somatomedin activity was 
estimated as described in this chapter, section D. 
RESULTS 
Plasma Somatomedin 
Since Daughaday et al. (1959) found maximal SM values on the 4th and 5th day ofGH 
* The HGH, clinical grade, was extracted by Organon N.V. and kindly supplied by the 'Nederlandse 
Groeistichting' (Dutch Growth Foundation). 
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treatment, plasma obtained on day 4 was tested. In order to correct for age differences 
(Du Caju and Van den Brande, 1973) results are expressed as the potency ratio to the 
mean normal for age (which is 1.00 by definition). The results are represented in Fig. I 0. 
Dl and D2 start from extremely low levels(< 0.14) and reach the normal range at the 
highest dose (Dl : 1.13, D2: 0.83). Pl and Nl rise from slightly subnormal to supernor-
mal values (Pl : 0.64 to 1.83, Nl : 0.63 to 1.47). P2 and N2 increase their plasma SM to 
the normal on the lowest dose of HGH without exceeding it on higher dosages (P2 : 0.40 
to maximally 0.86, N2: 0.71 to maximally 0.99). 
Fig. 10 
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Plasma somatomedin levels (SM) and average total urinary OH-proline excretion (± 1 SEM) during 
consecutive periods of HGH administration at increasing dosages. SM is expressed as the potency ratio 
of the plasma of the patient to the average obtained in plasma of children of the same age (horizontal 
line). OH-proline values are compared with the average ± 1 SEM obtained in 9 children of the same age 
range. 
Note the similarity of the individual dose-response curves for both parameters and the importance of 
the differences between patients. 
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Urinary hydroxyproline excretion 
In spite of the collagenfree diet the OH-proline varied considerably from day to 
day. Expressing the results of any given patient as the OH-proline/creatinine ratio 
reduces this variation (Fig. II). However, Zorab et al.(l970) reported a good correlation 
with growth rate when the data are expressed in absolute excretion of OR-proline. Jasin 
et a!. (1962) and Job eta!. (1966) had previously demonstrated the importance of 
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Urinary total hYdroxyproline excretion in two extremely GH deficient patients (Dl and D2) during 
7-day periods of treatment with increasing doses of HGH. The horizontal line represents the normal 
mean ± SEM obtained in 9 normal children of the same age range. Note the reduction of the 
day-to-day variation when the data are expressed as mg/g creatinine instead of mg/m2 /day. 
correcting for body surface area when comparing individuals. Hence, the large variation 
resulting from expressing the data as mg/m2 /day was accepted. 
Contrary to the expectation the OR-proline excretion did not reach a plateau within 
each study period. To allow comparison with SM levels, results on days three to five of 
each study period were averaged (Fig. I 0). In each patient the pattern of the dose-respon-
se curve is similar to the one obtained for plasma SM. The severely GH deficient children 
start from very low values (Dl : 8.6, D2: 7.2) and gradually approach the normal range 
on the highest dose of HGH (Dl : 39.2, D2 : 34.3). The four remaining patients are all 
close to the normal range during the baseline period. On treatment P 1 and N 1 more than 
double their values (PI : 34.5 to 100.07, Nl : 34.5 to 71.9) while the two others show 
only a minimal rise (P2: 45.6 to maximally 53.1, N2: 45.7 to maximally 66.2). The 
overall correlation between SM and OH-proline is visualized in Fig. 12. In spite of the fact 
that the data of P2 and N2 position slightly to the left of the others, a linear relationship 
is found with a correlation coefficient r = .89. 
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Fig. 12 
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OH-proline excretion as a function of plasma SM. All SM values (potency ratio to the normal for age) 
and the average OH-proline excretion on days three to five of each treatment period are included. The 
patients who responded poorly to GH administration (P2 and N2) are indicated with +. Their 
OH-proline excretion in the presence of a given amount of SM is not grossly different. Linear 
regression on all points : y = 49.7 x + 5 .3. 
DISCUSSION 
Studies of the responsiveness to short term GH administration have primarily been aimed 
at quantitating the degree of GH deficiency in short children (Daughaday and Parker, 
1963; Wright et al. 1965, Prader et al. 1968; Clayton et al. 1971 and Zachmann et al.,l972). 
The purpose of this pilot study was to investigate if we could elicit a similar dose-related 
response in hypopituitary patients with respect to somatomedin levels as had been 
obtained by Almqvist (I 960), and how these would correlate with the changes in total 
urinary hydroxyproline excretion. The inclusion of patients in whom GH-secretion was 
either limited but not absent or apparently normal, was aimed at screening for a 
difference in the character of such a relationship, either in terms of SM-generation or with 
respect to the hydroxyproline excretion. 
The measurement of somatomedin in plasma has now reached an acceptable degree of 
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precision (see same chapter, section D). In addition to the studies of Almqvist (1960) 
mentioned above, Daughaday and Parker (1963) had found an increase of SM of varying 
magnitude during shortterm administration of GH to short children. In general they 
noticed the best growth response to longterm treatment in the patients in whom the 
baseline SM value was low. This was confirmed by Wright et a!. (I 965). Hall (1972) found 
a good correlation of SM levels and growth velocity in GH treated children. 
Urinary OH-proline excretion was chosen as an index of a, presumably SM-mediated, 
periferal GH effect. This parameter has amply been demonstrated to be GH dependent 
(Jasin et a!. 1962; Job eta!. 1966; Wright et al. 1965 and others). lts selection had 
become possible by the development of the Hypronosticon-test® (Organon), which is as 
accurate as previous methods and much easier to perform (Goverde and Veenkamp, 
1972). 
In the two children with extreme GH deficiency, who can be anticipated to have a normal 
responsiveness, curves are obtained which are very similar in both, in spite of differences 
in age and skeletal maturation. They show a close to linear relationship of both SM levels 
and OH-proline excretion to the logarithm of the dose ofGH administered (Fig. 1). There 
is an excellent linear correlation between SM and OH-proline (r = 0.95). 
Amongst the four remaining children, two responded well (Pl and Nl), whereas the 
others barely changed their plasma SM levels or their OH-proline excretion. This diffe· 
renee in responsiveness was quite independent of the maximal plasma GH levels obtained 
during the diagnostic studies. The significance of this finding in terms of the pathogenesis 
of their short stature is limited since the reproducibility of these observatiOns has not yet 
been investigated. In particular, the question of the prognostic value of a positive 
metabolic response during shortterm treatment, with respect to growth response on 
longterm treatment should be treated with caution. The N-retention test developped by 
Prader et al. ( 1968) segregates most GH deficient patients from normals. Nevertheless, it 
does not allow quantitation of the degree of the deficiency (Clayton eta!. 1971). Since 
SM levels and OH-proline excretion are closely related to skeletal growth, they may prove 
to be better prognostic parameters. The studies of Daughaday and Parker (1963) suggest 
this. However, at present longterm treatment undoubtedly provides the best test to 
diagnose partial GH deficiency (Tanner eta!. 1971). 
The heterogeneity of the results obtained in the four patients who have no extreme 
GH-deficiency suggests individual differences with respect to their capacity to generate 
somatomedin in response to acute Gil-stimulation. This perhaps represents the most 
promising aspect of this pilot study. The overall good correlation between plasma SM and 
OH-proline is also of interest since it suggests a normal SM/collagen interaction in the 
patients without GH deficiency. It also indicates that in GH-deficient patients, where the 
correlation coefficient was the highest, urinary OH-proline measurements may have the 
same value as the measurement of somatomedin. This cannot a priori be said for non 
GH-dependent growth failure. It is our intention to perform a larger number of observa-
tions, with longer study periods and higher dosages of HGH, in order to test the validity 
of the impressions obtained in this pilot study. 
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SUMMARY 
Six children with short stature and varying maximal plasma growth hormone (GH) levels 
on stimulation were given clinical grade human growth hormone (HGH) at dosages of 0, 
2, 4 and 8 mg/m2 /day in consecutive periods of 5 to 7 days duration. Plasma somato-
medin (SM) levels, expressed relative to the normal for age, and total urinary OH-proline 
excretio.a (OH-P), corrected for body surface area, were monitored. Dose related response. 
curves were obtained which were almost identical for both parameters. In the two 
severely GH deficient children starting values were very low (SM: < 0.14, av. OH·P: 
7.8). They progressively approached the normal range on increasing doses of HGH 
(SM: 0.98, av. OH-P : 36.7). Of the four remaining children, two started in the subnormal 
range (SM : 0.63, av. OH-P : 34.5) and more than doubled their values on the highest 
dose of HGH. The two remaining children, starting with comparable SM, and somewhat 
higher OH-P values (SM : 0.55, av. OH-P : 45.6), showed only a slight increase without 
exceeding the normal range (SM : 0.84, av. OH-P : 52.3). 
In these four patients there was. no correlation between maximal plasma GH on stimula-
tion and the response to acute GH administration. The correlation coefficient of the. 
SM/OH-proline relationship of the pooled data of all patients was 0.89. 
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G. Primary somatomedin deficiency. A case report* 
Patients presenting with the clinical appearance of growth hormone deficiency, but in 
whom high levels of immunoreactive growth hormone were found, have first been 
described by Laron, Pertzelan and Mannheimer (1966). Since then, additional patients 
were reported by Laron, Pertzelan and Karp (1968), Merimee eta!. (1968), Tanner et a!. 
(1971), Najjar et al. (1971), Elders et a!. (1971) and New et al. (1972). This paper 
describes a similar patient and adds evidence suggesting an overall and specific non 
responsiveness to growth hormone. 
Patients 
The propositus, BK, a white boy, was born at 37 weeks gestation. Pregnancy had been 
complicated by hypertension during the last weeks. Birth weight: 3250 gram(+ 1.0 SO), 
length: 44 em (- 2.6 SO) (Usher and McLean, 1969). 
During the first days of life he was noted to drink poorly and to vomit occasionally. 
Psychomotor development was normal. Growth was slow from early in life (Fig. 13). At 
the age of two years he had documented hypoglycemic spells for which he was given 
cortisone (5 mg/day). An attempt to increase his growth rate with Orgabolin®Organon 
0.5 mg/day during six months failed. Cortisone was discontinued at the age of six years 
when Perthes-like deformaties were discovered at both hips. All treatment was withheld 
until he was 10 years and 3 months when he was admitted for the present studies. Family 
history is negative for short stature. Fathers height: 170.7 em (-1.1 SO), mothers 
height: !55 .7 em (- 1.7 SO)(Van Wieringen et al. 1968). There is no consanguinity. 
PL, another white boy, 6 years and 4 months old at the time of diagnostic studies, with 
severe hyposomatotropic dwarfism and of similar body size as BK, was selected to serve 
as a control. He was born by cesarean section, 3 weeks post term after presentation in 
breech position. Pregnancy had been complicated by hypertension after the 36th week. 
Birth weight: 3500 gram (equal to the mean for gestational age), length: 50 em (-1.5 
SD) (Usher and McLean, 1969). 
During the first days of life he drank poorly and vomited occasionally. He was noticed to 
grow slowly. (Fig. 13). His psychomotor development was quite normal. He has had no 
history of hypoglycemia and had received no medications before admission to the 
hospital. Family history is negative for short stature. The parents are full cousins. 
* These studies were done in collaboration with M.V.L. Du Caju, H.K.A. Visser, W. Schopman, 
W.H.L. Hackeng and H.J. Degenhart and will appear in Archives of Diseases in Childhood. 
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Height is plotted against Dutch growth standards ('Van Wieringen et al., 1968). Growth-hormone 
administration causes only a slight increase in growth rate in the propositus (BK). The control patients 
(PL) with isolated GH deficiency responds to GH-treatment with a pronounced growth spurt. 
36 
Materials and methods 
Growth hormone and insulin were measured with a charcoal dextran radioimmunoassay 
(Schopman and Hackeng, 1971). Urinary total nitrogen, calcium, phosphorus, creatinine 
and 17-hydroxysteroids, as well as bloodglucose and free fatty acids were measured using 
routine methods (respectively Fawcett and Scott, 1960; Dunsbach, 1963; Fiske and 
Subbarow, 1925; De Vries and Van Daatselaar as described by Gorter and De Graaf, 
1955; Degenhart, 1973; Schmidt, 1963; Ko and Royer, 1967 and Korovina et al., 1966). 
Total urinary hydroxyproline was determined with the Hypronosticon test® (Organon) 
(Goverde and Veenkamp, 1972). Plasma somatomedin was measured with a double 
isotope technique, using hypophysectomized rat or normal monkey rib cartilage (same 
chapter, section A). 
For the electrofocusing experiments a LKB 8102 Ampholyne column (440 ml) was used 
with LKB ampholite ranging from pH 3 to 6. The procedure was as described earlier (see 
this chapter, section A2). Equilibration time was between 60 and 120 hrs. Fractions were 
tested for their growth hormone content by radioimmunoassay. 
RESULTS 
a. Physical examination and ~aseline studies. 
The physical appearance of both boys was very similar (Fig. 14a). The abnormalities were 
more pronounced in BK than in PL. Both were short, obese and reasonably well 
proportioned. Some details are represented in Table 4. Their faces were small. Particularly 
BK's ears were disproportionally large. Teeth were in poor condition. Thoracic and 
TABLE 4 
Anthropometric data before and during treatment. 
BK PL 
Age (years) 11.1 11.6 12.2 13.3 7.3 7.8 8.4 9.5 
Time after initiating growth 
hormone treatment (years) 0 0.50 1.12 2.23 0 0.51 1.09 2.25 
Length (em) Supine 87.8 91.2 93.8 98.0 83.0 90.6 96.0 
Standing 90.5 95.3 103.0 
Span (em) 88.0 90.2 97.0 97.0 81.5 88.5 96.0 102.0 
Headcircumference (em) 51.0 51.5 51.5 51.6 48.2 48.3 48.8 49.4 
Weight (kg) 15.7 17.9 19.0 20.0 10.2 11.3 12.8 15.5 
Skinfold thickness 
%of initial 100.0 91.1 90.5 99.6 100.0 62.3 59.3 58.4 
37 
Fig. 14 
a. The propositus (BK-Jeft) and 
the control patient (PL-right) 
before treatment. Obesity was 
more pronounced in BK. Other-
wise their appearance was very 
similar. 
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b. The sella turcica was different: 
BK's sella (left) showed an im-
pression of the floor of the sella, 
whereas PL's (right) was small but 
otherwise normal. 
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abdominal examination was not relevant. Both children had small external genitalia with 
a rather short penis (BK 2.5 em, PL 1.5 em) a hypoplastic scrotum, the content of which 
could not with certainty be identified as testes. Eye grounds, visual fields and detailed 
neurological examination were all witin normal limits. Skeletal age was 5 yr. 0 mth 
(5 yrs. 2 mths. retarded) in BK, and 2 yr. 10 mths. (3 yrs. 7 mths. retarded) in PL 
(Greulich and Pyle, 1959). On X-ray examination, the skull bones were found to be very 
thin. Whereas PL's sella was small, in BK impression of the floor of the sella suggested a 
large pituitary gland (Fig. 14b). 
Baseline laboratory examination: 
Thyroid and adrenal function (BK respectively PL): PBI: 4.1 and 5.0 }.(g 0/0 . 131 !-uptake: 
30 and 23,4% of the dose after 24 hrs. Metyraponetest (maximal 17 ·OH steroid excretion 
on 250 mg at 4-hourly intervals for two days): 6.9 and 5.4 mg/m2 /24 hrs. All these 
results are normal. 
Plasma Growth Hormone was measured during intravenous infusion of arginine-mono-
hydrochloride (0.5 g/kg I.V. infused in 30 minutes), and with insulin induced hypo· 
glycemia (0.05 U/kg I.V.; bloodglucose fell to 51% of the initial value in BK and to 65% 
in PL), PL showed almost no response, reaching a maximum value of 2 MU/ml (I s1 lRP 
for Human Growth Hormone) during arginine infusion. BK in contrast had very high 
baseline values (average 69 MU/ml, range 60 - 76) which rose further to the extreme 
level of 508 MU/ml during insulin induced hypoglycemia. 
Plasma Insulin levels were also measured during the arginine infusion test and were low in 
both cases. Although their peak values were similar (BK: 8, PL: 9 MUfml, BK had a sustained 
baseline level between 4 and 6 }.(U/ml, whereas in PL the baseline was less than 1 MU/ml. 
Plasma Somatomedin measured in the hypophysectomized rat assay was equally low for 
both patients as compared to two acromegalies. This low value was found as well when 
3 5 S-sulfate as when the 3 H-Thymidine incorporation was used as an index of somatome-
din activity (Fig. 15). 
b. Short term metabolic studies (Table 5 and Fig. 16). 
Human Growth Hormone (HGH), clinical grade* was administered at a dose of 8 
mg/m 2 /day at 8 p.m. for seven days. Results obtained from the day after the second 
injection on have been selected for comparison with the baseline data, except for 
OH-proline excretion which is known to change slowly during GH treatment (Van 
Gemund et a!., 1969; see also chapter two, section F). For this reason only the data 
obtained after the fourth administration of HGH were included. During these studies the 
patients were hospitalized and kept on a calorie and N-constant diet. 
Fasting blood glucose and free fatty acids were only slightly affected. Blood glucose 
increased somewhat in the control and not in BK. Fatty acids did not change significant-
ly. 
The urinary excretion of Ca and P is expressed as their ratio since this reduced the daily 
* The content in immunoreactive HGH of this preparation is 1.45 1st IRP/mg. 
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fluctuation considerably. A slight but significant increase was noted in BK, while PL 
showed a very large rise. 
The urinary N-creatinine ratio fell slightly in BK and drastically in PL. The drop was 
significant for both patients but the differences between them were large. 
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Fig. 15 
Plasma somatomedin activity measured in the hypophysectomized rat assay using a dual labeling 
procedure. Within the limits of the concentrations used no increased incorporation of 3 5 S-sulfate or 
3 H-Thymidine occurs with plasma form BK nor PL while the plasma from two acromegalies is very 
stimulatory. 
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Fig. 16 
Plasma somatomedin activity measured in the normal monkey assay using a dual labeling procedure. 
Plasma from BK and PL before starting treatment (no. ~) and on the 4th - 5th day of HGH 
administration at 8 mg/m2 day are compared. Note that the dose response curve obtained with plasma 
from BK does not change in contrast to the potency of PL's plasma which increased markedly. 
3 s $-sulfate and 3 H-thymidine incorporation were identical (the latter is not shown). 
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TABLE 5 
Effect of shortterm growth hormone administration* 
P~values** 
baseline on treatment baseline versus 
mean ± SEM (n) mean ± SEM (n) %change treatment 
Fasting blood BK 76.75 ± 3.7 (4) 72.30 ± 2.0 (5) 5.8 n.s. 
glucose (mg %) PL 64.25 ± 5.2 (4) 81.04 ± 2.24 (5) + 26.1 < 0.05 
Fasting plasma BK 1.080 ± 0.060 (4) 1.248 ± 0.124 (5) + 15.6 n.s. 
FFA (mEq/L) PL 1.231 ± 0.270 (4) 1.375 ± 0.116 (5) + 11.7 n.s .. 
Urinary Ca/P BK 0.060 ± 0.003 (3) 0.085 ± 0.012 (5) + 41.7 < 0.05 
ratio PL 0.085 ± 0.004 (3) 0.315 ± 0.038 (4) + 270.6 < 0.01 
Urinary N/creatinine BK 22.57 ± 0.34 (3) 19.44 ± 0.54 (5) - 13.9 < 0.005 
ratio PL 25.73 ± 2.51 (3) 10.50 ± 0.41 (6) - 59.2 < 0.001 
Urinary OR-proline/ BK 67.60 ± 3. 71 (3) 57.4 ± 2.37 (4) 15.1 < 0.05 
creatinine ratio PL 104.23 ± 5.60 (3) 197.6 ± 23.25 (4) + 89.6 < 0.01 
' 
dose of HGH: 8 mg/m2 /day. See text. 
** by Student t-test, n.s. =not significant. 
The urinary hydroxyproline/creatinine ratio decreased somewhat in BK and doubled in 
the control patient. 
Plasma Somatomedin was measured in pretreatment plasma and on the fourth day of 
GI-l-treatment. In baseline conditions both patients are indistinguishable. On treatment 
the somatomedin activity of PL rose to approximately three times the baseline levels, 
whereas BK remained unchanged, both when the results are expressed as 3 5 S~sulfate and 
as 3 H-Thymidine incorporation. 
c. Effect of longterm GH-treatment. 
Linear growth and skin/old thickness: Over periods of two years before and on treatment 
the growth rate of BK increased from 3.1 to 4.6 em/yr. as compared to a change from 
3.3 to 9.2 em/yr. in the control patient (PL). Over the same period of treat-
ment average ~kinfold thickness, measured with a Harpenden caliper and computed 
from measurements at eight sites (above the biceps, triceps and quadriceps and in the 
subscapular area bilaterally), after an initial drop to 90.5% of the initial value, increased 
again to 99.6% in BK, while it dropped to 58.4% in PL (Table 4). 
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Skeletal maturation advanced 2 yrs. 9 mths. in BK and 2 yrs, 6 mths. in PLover the same 
two year period. 
Plasma somatomedin activity. As is shown in Fig. 17 dose response curves with BK's 
plasma before treatment, after four days and six months of growth hormone administra-
tion are not different. 
Plasma growth hormone and insuline levels. An arginine telerance test was repeated in 
BK after six months of treatment. The test was done 36 hrs. after a HGH·injection. The 
results are shown in Table 6. Treatment has not resulted in a decreased endogenous HGH 
nor has it stimulated insulin secretion in response to arginine infusion. 
d. Some immunological and physico-chemical characteristics of endogenous 
growth hormone in BK. 
To study possible differences in immunological characteristics plasma was serially diluted, 
measured in the growth hormone radioimmunoassay and the slopes obtained were 
compared. No significant deviation from paralellism could be demonstrated (Fig. 18). 
In order to find possible differences in charge, plasma from BK was electrofocused and 
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Plasma was incubated over a wide range of concentrations in the normal monkey assay using 
3 5 $-sulfate incorporation as index. Dose-response curves obtained with plasma before treatment, after 
four days of administration of HGH (8 mg/m 2 /day), and after six months of treatment with HGH 
5 mg bi-weekly are identical. In order to demonstrate that this assay would pick-up an active sample. 
PL's plasma on the 4th day of HGH treatment was also measured. 
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TABLE 6 
A1ginine infusion before and after six months of growth hormone administration. 
Time -15 -I +15 +30 +45 +60 +75 +90 +120 +150 
Plasma Growth Hormone 
before treatment 63 75 105 118 170 470 508 295 133 
after six months 
of treatment 217 216 141 192 315 228 180 198 222 198 
Plasma Insulin 
before treatment 6 4 4 6 8 6 4 4 5 
after six months 
of treatment 4 2 2 3 4 2 2 2 2 2 
Arginine hydrochloride 0.5 g/kg bodyweight I.V. over a 30 min. period after overnight fast 
Time expressed in minutes before (-)and after(+) the initiation of the infusion. 
Growth Hormone is expressed as 1-L U 1st I.R.P ./ml, insulin as J.l U/ml. 
compared both to plasma from an acromegalic and HGH (same preparation as used for 
treatment). GH was localized by radioimmunoassay. 
Initially, GH in BK's plasma focused at a rather wide peak with a suggestion of two 
maxima (Van den Brande et al., l97la). After improving the technique by the selection 
of the more appropriate pH-range of 3 · 6 instead of 5 - 8, and using the same plasma 
sample a sharp single peak was repeatedly found at an average pH of 5.03. In acromegalic 
plasma, GH focused in a single zone at an average pH of 5.01. Finally, HGH, clinical grade 
yielded a broad zone of immunoreactive material with a maximum at pH 4.98. Examples 
are shown in Fig. 19. Within the limits of the technique we find the GH from these three 
sources to behave indistinguishably. 
DISCUSSION AND CONCLUSIONS 
At first most of the patients studied by Laron et al., (1968) seemed to respond to 
exogenous HGH with N·retention, lipolysis and increased growth rate. More recently 
however, after a longer period of observation, the authors concluded that the metabolic 
and growth response of their patients was variable but mostly lacking (Laron et al., 
1971 ). This is an agreement with the findings by others (Merimee et al., 1968, Tanner et 
a!., 1971, Najjar et al., 1971, Elders et al., 1971 and New et al., 1972). Laron et al. 
(1971) favour the hypothesis that the growth hormone molecule in such patients might 
have an abnormal structure, lacking biological activity but with the preservation of its 
immunological characteristics. The subnormal response to exogenous HGH could be the 
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Fig. 18 
Plasma from BK was serially diluted and measured in the HGH-radioimmunoassay. Each of the points 
on the standard curve is an average of four determinations. The plasma was measured in duplicate at 
each dose-level. HGH is expressed in !J U 181 LR.P. of Human Growth Hormone. No deviation from 
parallellism can be demonstrated (F: 4 .8,- P: 0.05 ). 
consequence of an unsuccessful competition with the endogenous molecule for binding 
sites. Daughaday et al., (1969) found low plasma somatomedin (SM)-levels as well before 
as on treatment with HGH in Laron's patients. They suggested that the lack of SM-
generation may be involved in the pathogenesis of the growth failure, while the other 
abnormalities such as lack of lipolysis, N-retention and calciuria may be the expression of 
a more generalized defect in growth hormone response. New et al., (1972) came to similar 
conclusions. Our patient also presents with a complete picture of hyposornatotropism, 
which not only includes short stature and the typical appearance, but also a documented 
hypoglycemia, insulinopenia and low plasma somatomedin levels. Noteworthy is the low 
lenght at birth with slightly increased weight. Laron et a!. (1968), also found low birth 
length in half of their patients. This suggests some GH dependency of intrauterine growth 
at the end of pregnancy. 
The endogenous growth hormone, present at very high levels in plasma, cannot be 
distinguished from nonnal growth hormone, neither from its immunological behaviour, 
nor from its isoelectric point. 
Our results during short term treatment with HGH, at high dosage, confirm previous 
reports: changes of metabolic indices of growth hormone effect such as bloodglucose, 
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N-retention, calciuria and hydroxyproline excretion are minimal or absent. Somatomedin 
is low before and on treatment. The finding of others (Laron eta!., 1971, Tanner et al., 
1971, Najjar et al., 1971 and New et al., 1972) that chronic treatment did not induce the 
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Examples of electrofocusing of human growth hormone. From left to right: HGH (clinical 
grade, same preparation as in the metabolic studies, 0.72 mU), 2 ml of plasma respectively from 
patient BK and an acromegalic. In repetitive experiments the GH of all three preparations was found 
between the extremes of pH 4.93 and 5.14. Average peak-positions were HGH: 4.98, BK: 5.03, 
acromegalic: 5.01. (For technical details see text.) 
expected increase in growth rate was also confirmed in our patient. In addition, similarly 
to the observation of Tanner eta!. (1971), we found a slight temporary decrease of the 
skinfold thickness, measured with the Harpenden caliper, followed by an increase. By 
radiography however, Tanner et al. (1971) noticed little change in fat or muscle. While 
Elders et al. (1971) reported that in acute conditions the endogenous GH·secretion could 
not be suppressed by exogenous administration of the hormone, we found that prolonged 
treatment was not effective in this regard either. Insulinopenia and low plasma somato-
medin levels, which had been shown by others to be resistant to acute GH-treatment 
(Laron et al., 1971, Elders et al., 1971 and New eta!., 1972) were still unchanged after 
six months of administration of the hormone. 
All these findings suggest a specific and overall impaired responsiveness to growth 
hormone. No evidence is present supporting the hypothesis of an abnormal endogenous 
GH-molecule. 
While all effects of GH are diminished, its failure to induce SM seems to have the most 
dramatic consequence. Since SM is supposed to mediate the growth promoting effect of 
GH (see same chapter, section C), the extreme short stature of our patient should most 
likely be attributed to his SM-deficiency. 
Studies of the characteristics of the GH-receptors in these patients, and evaluation of 
their responsiveness to exogenous SM should contribute to the elucidation of the 
pathogenesis of this syndrome. 
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SUMMARY 
A child presenting with the clinical features of hyposomatotropism but with high 
immunoreactive plasma growth hormone is described. During shortterm administration of 
human growth hormone (HGH) his response with regards to fasting bloodglucose and free 
fatty acids, plasma somatomedin, urinary excretion of calcium, nitrogen and hydroxy~ 
proline were minimal or absent. Six months of treatment with HGH did not reduce the 
endogenous HGH secretion. Insulin secretion had not increased and plasma somatomedin 
levels remained extremely low. Over a period of two years of treatment, growth response 
and loss of subcutaneous fat were minimal. On serial dilution in the radioimmunoassay, 
his GH-molecule yielded a parallel line with the HGH-standard. In electrofocusing 
experiments the GH·molecule positioned at the same pH-range as GH in acromegalic 
plasma and the major peak of clinical grade HGH (average 5.03 versus 5.01 and 4.98). 
It is concluded that an overall and specific diminished responsiveness to HGH is present in 
this patient. This includes a lack of generation of somatomedin, which is thought to be 
the cause of his short stature. No evidence suggesting an abnormality of the GH-molecule 
was found. 
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Chapter three 
CURRENT KNOWLEDGE OF SOMATOMEDIN 
Only a few articles have appeared recently reviewing the subject (Daughaday and Garland, 
1972; Hall, 1972 and Grant, 1972). Since much progress has been made during the last 
year, it seemed of interest to summarize the current status of our knowledge of 
somatomedin. 
1. Somatomedin-assay 
Most present methods for estimating SM in vitro are derived from the technique described 
by Salmon and Daughaday (1957), which measures 35 S-sulfate incorporation into chon-
droitine-sulfate in rib cartilage of hypophysectomized (hypox) rats. Its imprecision and 
laboriousness had lead many investigators into a search for a better method. Y de ( 1968) 
used the cartilage of normal fasted rats. This simplified the technique and yielded a 
slightly better precision (av. s;b : 0.20 as compared to ± 0.26 in the hypox rat-assay). 
Recently, Alford eta!. (1972) modified the Yde-technique further. At the end of the 
incubation, the cartilage is digested and precipitated onto paperstrips, which facilitates the 
washing procedure. Fujisawa (1964), using hypophysectomized puppies, by-passed the 
important inter-animal variation of the other methods, since cartilage from a single animal 
sufficed for one assay. However, the magnitude of the response in this tissue to SM is very 
small. 
Hall ( !970) uses the pelvic rudiments of chicken embryo's. This shortens the procedure 
with one day but does not improve the precision and is less sensitive than the hypo· 
physectomized rat assay. 
Our own method (chapter 2, E), combines many of the advantages of these modifications 
since the manipulations have been reduced to a minimum and the precision of the 
technique has been improved considerably. 3 H-Thymidine and 35 S-sulfate incorporation 
are measured simultaneously. The average precision (s/b) of the latter, which is the best 
parameter, is 0.15. The sensitivity is similar to all other methods except for those which 
use hypophysectomized animals. Garland et al. ( 1972) have used suspensions of chon-
drocytes liberated from pelvic leaflets of chicken embryo's. They showed a marked 
stimulation of 3 H-Thymidine incorporation into DNA when the cells were incubated with 
increasing doses of plasma. However, the correlation between the results in this system 
and those in the other SM-bioassays remains to be established. 
A quite different approach was made by Herbai et a!. (1970), who utilized the in vivo 
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incorporation of 3 5 S-sulfate into the costochondral junctions of mice as an index of 
sulfation activity. This method is particularly suited for studying physiological variations 
and in vivo experimentally induced changes (Herbai eta!., 1970; Herbai, !971a, !97!b 
and !971c). All these techniques have the disadvantage of not being specific. Many 
substances other than somatomedin have been recognized to influence sulfation and 
DNA-replication in cartilage. The most important amongst them arc insulin, cortisone and 
amino acids (Layton eta!., 1951; Murphy eta!., 1956; Salmon and Daughaday, 1951 and 
1958; Salmon eta!., 1968; Koumans and Daughaday, 1963). Their influence will be 
reviewed in detail by Du Caju in his thesis (to be published). The lack of specificity 
necessitates carefully controlled experimental conditions before any definitive conclu-
sions can be drawn from the results obtained with the current assay-techniques. 
A radioimmunoassay may by-pass this problem. Purification of SM is now in such a stage 
that its development can be expected soon. An alternative possibility is raised by the data 
of Hintz et a\. (1972a), which suggest that somatomedin and insulin compete for the 
same receptor sites on chondrocytes. This phenomenon could potentially be used for the 
development of a radio-receptor assay with 1 2 5 I -insulin as the marker. At present apart from 
somatomedin, no other animal substances than insulin, pro-insulin and substituted 
insulins have been demonstrated to compete with 12 5 l-insulin for binding to receptor 
sites. Such a technique has the potentiality of being highly specific. The combination of 
measuring SM by bio-assay and either a radioimmuno- or radio-receptor assay should be 
particularly interesting for the study of those conditions in which the SM-values by bio-
assay have been unexpectedly high or low (Du Caju and Van den Brande, !973). 
Moreover, a radioreceptor assay for SM in which the cells of patients represent the 
variable, should be of great value to investigate these conditions where the SM/target-
organ interaction is suspected to be disturbed. 
2. Characterization and purification of sornatomedin 
A. Characterization 
Most of the studies on the physical characteristics of SM have been on either human ur 
rat plasma or -serum. Our studies on plasma SM in different animal species did not revc~d 
qualitative differences in the somatomedin of a series of mammals (chapter 2. [)). :vtorc 
recently, studying SM in porcine plasma with acid-ethanol extraction, gelfiltration, ion 
exchange chromatography and ultrafiltration, we have been unable to demonstrate any 
difference with human SM (to be published). This suggests at least a close structural 
similarity. 
The structure of SM is not known, but many of its characteristics have been described. 
I. Identity ofsulfation and DNA-replication stimulating activity. In the course of all our 
experiments we have never found separation of SM into a fraction which stimulates 
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sulfate incorporation and another stimulating DNA-replication. This suggests that both 
these effects of SM may reside in the same molecule (chapter 2, A). 
2. Molecular size._ In native rat plasma, SM behaves as a large molecule. This was already 
apparent from early studies in Daughaday's laboratory which demonstrated that SM was 
not dialysable and resided in the macromolecular fraction both by ultracentrifugation and 
by chromatography on Sephadex G-25 (Salmon and Daughaday, 1958; Daughaday and 
Kipnis, 1966; Koumans and Daughaday, 1963). This was confirmed by BaJa eta!. (1970) 
and by our own studies in plasma from acromegalies (chapter 2, A). 
In line with this is its retention by ultrafiltration membranes with an exclusion limit of 
50,000 daltons (chapter 2, A). Somatomedin, extracted from plasma with 20% ethanol 
and subsequent chromatography on DEAE-cellulose was recovered on Sephadex G200 
(pH 7.4) in a zone suggesting a M.W. between 9,500 and 35,000 (chapter 2, A). Acid 
ethanol extraction yields an active fraction of smaller size (VanWyk eta!., !969). When 
such an extract is subjected to gel filtration on Sephadex G100 at pH 7.5 the apparent 
M.W. is between 4,000 and 12,400 (chapter 2, A). The same procedure with 1% formic 
acid as eluent yields an active fraction with an apparent M.W. between 4,000 and 8,000 
daltons (Hall, 1972). These discrepancies suggest that SM is either bound to a larger 
carrier in plasma or aggregates in neutral or alkaline conditions. 
3. Charge. The behaviour of SM on ion exchangers, starch gel, high voltage electro-
phoresis, and iso-e1ectric focusing suggested that the main component responsible for SM 
activity in plasma is a molecule with an isoelectric point between 6.6 and 6. 7. By starch 
gel electrophoresis, iso-electric focusing and DEAE-chromatography, a minor active 
fraction was recovered, which was more acid and focused at a pH of 5.2 (chapter 2, A). 
No further information is at present available about other qualitative differences between 
these two fractions. The findings are similar irrespective of whether the preparation used 
was native plasma or acid-ethanol extract. 
4. Peptide nature.We found pronase to destroy the biological activity of SM in a semipuri-
fied fraction (obtained by DEAE-cellulose chromatography) of acromegalic plasma, and 
concluded that SM was either a peptide or needed a peptide linkage for its expression 
(chapter 2, A). This was confirmed by Salmon (1972): Exposure of an active fraction, 
obtained by heating acidified normal rat serum, to trypsin destroyed all biological 
activity. 
5. Stability. Somatomedin is relatively stable. It tolerates pH extremes (from 2 to 10) 
(chapter 2, A). Its activity is lost by heating to 80°C for 30 min. in an alkaline solution 
(chapter 2, A). In contrast, after acidification it is not destroyed even when exposed to 
!00°C for 15 min. (Salmon and Duvall, 1970). 
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B. Isolation 
Based on these observations, different isolation schemes have been developed, either 
starting with acid-ethanol extract (Van Wyk et al., 1969) or with acidified and heated 
plasma (Salmon and Duvall, 1970). The GH-dependency of extracts obtained by heating 
acidified plasma has been demonstrated (Salmon and DuvalL 1970). This has not been 
verified for acid-ethanol extracts. 
For subsequent isolation many techniques have proven to be efficient: gel filtration on 
Sephadex G75 (Van Wyk et aL, !972; Hall, 1972), chromatography on CM- and 
DEAE-cellulose or -Sephadex, fractionation on Dowex-50 (Chapter 2, A, Salmon and 
Duvall, !970 a; Hall, 1972) and high voltage electrophoresis (chapter 2, A, Hall and Uthne, 
1972). Liberti (1970) used sequential ultrafiltration on Diaflo-membranes of frozen and 
thawed cow-plasma, and recently reported the successful utilization of the binding of SM 
to cartilage, followed by its removal with concentrated salt solution (Liberti, 1972). 
The purest SM-preparation has been obtained thus far by Kerstin Hall (1972) who 
claimed 1 x 106 purification over native plasma. It migrated as a single band on 
polyacrylamide. Using a somewhat different scheme of isolation. VanWyk has obtained a 
preparation which is equally pure (personal communication). It can be anticipated that 
the amino acid composition and eventually the sequence of somatomedin will be known 
soon. 
It should be emphasized that large losses of biologically active material occur during these 
isolation procedures. It cannot be exluded at this time that some molecular species, 
structurally different, but with similar biological characteristics are lost in the process. 
3. Source of SM 
Many attempts have been made to discover the source of SM. Realizing that early binding 
of a hormone frequently reflects its site of action, we studied the distribution of 
12 5 I-HGH in young hypophysectomized rats 6 and 20 minutes after intravenous injection 
using whole body autoradiography (chapter 2, B). A high concentration of radioactivity 
was found in the liver, the kidney and in the zona glomerulosa of the adrenal cortex. 
Some accumulation was also apparent in the submandibular glands. Pretreatment with 
GH largely prevented accumulation in the liver and adrenal cortex and slightly in the 
submandibular glands, suggesting specific binding to these tissues. In contrast, the 
accumulation in the kidney was enhanced. 
Kidney. it had b-een demonstrated by others that GH is accumulated in the brushborder 
of the tubular cells in the kidney (Collipp et a!., 1966), which may be a reflection of 
reabsorption. Since the rate of glomerular filtration is enhanced by GH-administration 
(Gershberg, 1960; Becket a!.. 1964), increased reabsorption could explain the influence 
of pretreatment. McConaghey and Dehne! (1972) demonstrated GH inducible SM-likc 
activity in kidney perfusates of hypox rats. However, they also found kidney slices both 
from hypox and normal animals to release SM-like activity in large and equal amounts. 
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Further characterization of this material is necessary to investigate its relationship with 
plasma SM. 
Adrenal. The binding to the adrenal is likely to be associated with aldosteron production, 
which is enhanced by high doses of GH (Becket aL, 1957). Since adrenalectomized and 
hypophysectomized animals grow well on GH-treatment (Simpson et aL, 1944) the 
binding of HGH is unlikely to be related to SM-production. This would be in line with the 
findings of Bostrom et aL (I 955a) and of Hall and Bo~ovic (I 969), who were unable to 
extract SM from this organ. 
The submandibular gland has been shown to be essential for normal growth in many 
mammalian species (Narisimhan and Ganla, 1968). The possibility that this organ pro-
duces SM remains to be explored. 
The liver has been the subject of many studies. Bostrom et aL (1953) found homogenates 
of normal rat livers to stimulate sulfate uptake in rat costal cartilage. A long search for 
the identity of this material however proved it to be glutamine (Bostrom et aL, 1955b). 
Perfusion of normal rat liver and incubation of rat liver slices with bovine growth 
hormone stimulated release of a SM-like substance (McConaghey and Sledge, 1970; 
McConaghey, 1972). Rat liver slices, superfused with human growth hormone, also 
released SM-like activity (Hintz et aL, 1972b). Fractionation of it on Sephadex G-75 
revealed a major peak of activity with an apparent M.W. of 6,000- 12,000 and a minor 
peak in the M.W. < 2,000 range. Hall and Uthne (1971) found GH to stimulate the 
production of SM-like material during incubation with liver microsomes, which behaved 
like plasma SM on Sephadex G25. 
Although the identity of the SM-like activity from liver and in plasma has not been 
established, the evidence strongly supports the possibility that SM is produced in the 
liver. In agreement with this, is the rapid fall of plasma SM-activity after partial 
hepatectomy, and its gradual return to normal during regeneration (Uthne and Uthne, 
1972) 
Muscle. Hall and Bo~ovic (1969) extracted SM-like activity from rat muscle and Hallet aL 
( 1970) found the characteristics of this material to be very similar to SM in plasma. 
In conclusion, the data suggest the release of GH-dependent SM from the liver, muscle 
and perhaps the kidney. Further studies on its identity with plasma SM are necessary. It is 
uncertain at present if other organs are involved as well. 
4. Factors influencing plasma SM levels 
A detailed review of the subject will appear in the thesis by Du Caju. Only some 
important points will be mentioned here. 
A. Normal variation 
Normal plasma somatomedin increases with age in children. Chesley (1962) demonstrated 
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that SM in cord blood was lower than in maternal serum. Almqvist and Rune ( 1961 ) and 
Kogut et al. (1963) obtained data suggesting a progressive increase during early child-
hood. This has been confirmed by studies in our own laboratory (Du Caju and Van den 
Brande, 1973). We found increasing values until the age of six years. After a slight rise 
until puberty when adult values are reached, the plasma levels remain constant through-
out life (Daughaday et al., 1959; Almqvist and Rune, !961 ). In none of these studies sex 
differences have been apparent. Some diurnal variation. without consistent circadian 
rhythm was noticed by Daughaday eta!. (I 959). 
B. Hormonal influences 
The major importance of f{rrnvth horrrwnc for the induction of SM has lung been 
recognized. In humans and in rats the time relationship between GH-udminis!ration and 
SM-generation have been studied in detail. Salmon and Daughaday { 1951) dcmonstr<ltcd ;1 
significant increase of plasma SlVl 6 Ius. after intraperitoneal administratio11 of buvinc 
growth hormone to hypophysectomized rats. Hall ( 1971) found a rise of pL.Jsma S!\.:j three 
hours after intravenous injection of human growth hormone to hypopituitary patients. 
Studies on the quantitative relationship between the dose of exogenous GH and plasm:1 
SM levels have been few. Almqvist (1960) obtained a dose rebted rcspunsc in three 
hypopituitary children during short term HGH-administration. Daughaduy and Parker 
( 1963) administered HGH to ten short children in two different dosages and found <I 
variable increase irrespective of the baseline levels in all but one. 
We studied the dose-response relationship between exogenous HGH and plasma SM levels 
in children with short stature who had varying maximal plasma GH levels during 
stimulation tests (chapter 2, F) in an attempt to segregate normal from <Jbnormal dose-
response curves. The results indicate that such studies may be developed into a tool to 
study clinical conditions. where SM-gcneration is suspected to be impaired. An extreme 
example is represented by the patient described in chapter :2, G, who is similar to those 
first reported by Laron et al. ( 1966). Such patients arc incapable of generating SM in 
spite of high endogenous GH (Daughaday eta!., !969; Laron eta!., 1971). In our patient 
no abnormality of the GH-molecule could be demonstrated, nor immunologically, nor by 
electrofocusing. 
The normal plasma SM levels in children with craniopharyngioma who are growing well in 
spite of low plasma GH, and in children with obesity, perhaps represent examples of the 
opposite situation (Du Caju and Van den Brande, 1973). 
Other hormones have been investigated for their effect on plasma SM. Thyroxine 
stimulates sulfation in rats (Murphy et al., 1956), but the data in humans is still equivocal 
Testosterone is probably without effect (own observation, to be published). ()estrogens 
suppessed the SM-activity in plasma of acromegalies (Wiedeman and Swartz, 1971). 
Insulin seems of little influence since SM values are normal or only slightly suppressed in 
untreated diabetics (Chesley, 1962; Jensen eta!., !963; Yde, 1964). 
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C. Nutritional status 
Some nutritional conditions have a profound influence on total SM-like activity in 
plasma. The low values found in malnutrition exemplify this (Van den Brande and Du 
Caju, 1972). Whether or not this is due to inhibitors as was demonstrated in the fasted rat 
by Salmon (1972), or to diminished SM-production remains to be examined. 
D. Other factors 
A series of other as yet undefined factors seem to influence plasma SM levels. This is 
illustrated by the low SM values which we found in morning samples of so-called 
dysmorphic dwarfs (children with minor or major congenital malformations and short 
stature), and surprisingly also in young children with cerebral gigantism, a syndrome 
recently identified by Sotos et al. (1964). The plasma SM lowering effect of partial 
hepatectomy has already been mentioned (Uthne and Uthne, 1971). Bostrom et al. 
( 1971) described increased plasma SM after repeated bleeding of rats. The significance of 
this finding is still obscure. A curious observation is the accelerated growth of hypo-
physectomized rats infected with Spirometra Mansonoides (Mueller, 1968; Steelman et 
al., 1970). Garland et al. (1971) did experiments which suggest that this parasite releases. 
an SM-inducer. Antibody formation to this inducer may be the cause of the short 
duration of the growth stimulation. 
The many situations in which SM levels are not correlated with plasma GH levels suggest 
that other modulating factors besides GH control plasma SM levels. One of the still purely , 
hypothetical possibilities is the existence of a negative feedback on SM-synthesis, 
operative in the absence of a metabolic effect in the SM-producing cell themselves. Many 
alternative mechanisms such as substances in blood influencing SM-synthesis or its effect 
in the bio-assay or changes in SM turnover could equally well be involved. 
5. Disappearance rate of plasma somatomedin 
Following hypophysectomy in the rat, somatomedin disappears from the plasma within 
24 hrs. The half-life of disappearance was found to be approximately 3 to 4 hours 
(Daughaday et al., 1968). Almqvist and Falkheden (1961) reported on three patients in 
whom they followed plasma SM after hypophysectomy. They found half-life times of9, 
10.5 and 18 hours. 
6. Biological properties of somatomedin 
The capacity of somatomedin to stimulate chondroitin sulfate synthesis in cartilage is 
used as point of reference by all authors when searching for other biological effects. It · 
should be emphasized that all such experiments have been using either native plasma or 
incompletely purified extracts. Moreover, as mentioned earlier, the GH-dependency of 
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many of these extracts has not been verified, which further limits the conclusions. 
The extensive in vitro studies by. Daughaday and Salmon and their collaborators have 
solidly established the stimulating effect of somatomedin on a series of specific functions 
of the cartilage cell (chondroitin sulfate synthesis, formation of protein polysaccharide 
complexes and conversion of proline into collagen hydroxyproline). They also established 
that RNA-synthesis was enhanced and demonstrated a wave of DNA-replication induced 
by somatomedin (Salmon and Daughaday, 1957; Salmon eta!., 1968; Daughaday and 
Mainz, 1962; Daughaday and Reeder, 1966). 
Salmon and DuVall (1970 b) demonstrated that the activity ofSM was not restricted to 
cartilage. They showed that partially purified fractions derived from acidified heated rat 
plasma stimulated protein synthesis in the diaphragms of hypophysectomized rats in vitro 
significantly more than did GH. Enhancement of transport of 14 C-et aminoisobutyric acid 
into muscle during in vitro incubation with acid ethanol extracts was observed by Hall 
and Uthne (1971). 
Salmon and Hosse (197!) reported a stimulatory effect of their preparations on the 
growth of HeLa cells. 
Fat pads also resp-ond to preparations with SM-activity. Raben eta!. (1971) demonstrated 
that there is a GH-dependent factor in serum which stimulates DNA-replication in this 
tissue. Hall and Uthne (1971) found acid-ethanol extracts, and preparations of higher 
purity derived from it, which had somatomedin activity, to stimulate 14 C-glucose 
conversion into 14 C02 . Similarly prepared fractions were found to cause inhibition of 
glycerol release from epinephrine-stimulated rat epidimymal fat pads by Underwood et a!. 
(1972). 
Only a few in vivo experiments have been reported. Hall and Uthne ( 1971) found a 
significant increase of the tibial epiphyseal width of hypophysectomized rats treated with 
a semipurified human SM-preparation for one week. Underwood et al., reported data 
suggesting a suppression of glycerol release in vitro from epididymal fat pads of hypo-
physectomized rats injected with partially purified human SM 4 hrs. before sacrifice. 
7. Relo.tion between somatomedin and substances with similar biological effects 
The spectrum of biological effects of somatomedin is very similar to that of insulin. This 
was recognized early by Salmon eta!. (I 968), who did extensive comparative studies 
between these two substances. Since insulin and SM could not be identical as judged from 
the failure of insulin antibodies to prevent the effect of SM, Salmon and DuVall ( 1970 b) 
wrote: 'One may suspect from these similarities that sulfation factor is identical with one 
or more plasma insulin-like factors defined in bioassay systems involving effects on 
muscle or adipose tissue.' Around the same time, VanWyk eta!. (1969) gave substance to 
this suggestion by showing that SM could be extracted from plasma by the same 
procedures as used for the isolation of NSlLA -S (the soluble fraction of non suppressable 
insulin-like activity) (Burgi eta!., 1966; Jakob eta!., 1968; Poffenbarger et a!., 1968; Van 
Wyk et a!., 1969)_ Hall and Uthne (1971) carefully studied the ratio of NSlLA-S to 
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SM-activity in the course of a series of isolation procedures and found it to be constant 
within the limits of the assay-techniques. The data thus far strongly suggest that both 
biological activities may reside in the same molecule. 
Similar observations were made by Pierson and Temin (1972) with regards to a substance 
named MSA (mitotic stimulating agent), which is responsible for the effect of calf serum 
on the mitosis of fibroblasts in culture. They used extraction procedures very similar to 
those used for SM for isolating this substance. Again the question is raised about the ' 
possible identity ofMSA and SM. 
Since all these substances are insulin-like in their effects, VanWyk and his collaborators 
(Hintz et a!., 1972a) set out to study the binding characteristics of SM to different cell 
and membrane preparations. Their results suggest that SM competes with 1 2 5 I -insulin for 
the same binding sites on rat fat cells, chicken embryo chondrocytes and cell free 
membrane preparation from rat livers. The displacement curves obtained with insulin and 
SM were parallel with a ratio of I U SM (defined as the activity present in one ml of their 
normal adult plasma pool) to 50 J.LV of insulin for fat cells, and I to 200 for liver 
membranes. Chondrocytes behaved differently since the displacement.curves with insulin 
and SM were dissimilar. SM was a much more effective competitor for binding sites than 
insulin. 
In fat cells, the ratio between insulin and SM in terms of their capacity to displace 
12 5 !-insulin corresponds well with the ratio of their biological effect as measured by 
glucose degradation. These data suggest that insulin and semi-purified SM, although 
similar in terms of the type of biological effects they can produce, derive their vastly 
discongruent profile from the greater or lesser affinity to the binding sites of different cell 
types. 
NSILA-S and MSA, which may be identical to SM, but also other substances such as nerve 
growth factor, erythropoietin and epidermal growth factor, which elicit similar metabolic 
effects albeit on different tissues, may obtain their specificity by a similar mechanism. 
With regards to insulin and SM, some evidence is available suggesting that they may exert 
their action through a common pathway, once binding has been established. it seems well 
documented now that insulin inhibits the stimulated activity of adenyl cyclase in purified· 
membrane preparations from liver and from isolated fat cells (Cuatrecasas, !972). The 
same appears now to have been demonstrated for somatomedin in the laboratories of 
Cuatrecasas and VanWyk (Cuatrecasas and Tell, 1973). The inhibition by cycle 3'5' 
adenosine monophosphate and theophylline of the .·effect of normal rat serum on the 
35 S-incorporation in chick embryo cartilage reported by Rendall et a!. (1972) is compa-
tible with Cuatrecasas' and VanWyks' findings. It is difficult however to fit this in with 
the slight but significant stimulation of sulfation in the same· tissUe by dibutyryl adenoSine 
3'5' cyclic phosphate in the absence ofSM reported early by Fujisawa (1964) and more 
recently by Adamson ( 1970) and Hall (1972). 
The possible role of SM in glucose homeostasis and fat metabolism is uncertain. Much 
evidence has been presented that NSILA-S and SM may be identical. NSILA-S, although 
very active in terms of glucose and fat metabolism in vitro and in vivo after purification, 
seems to play little or no role in glucose homeostasis in the organism in its native 
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state (Oelz, Froesch et al., 1972). It seems very well possible that the true physiological 
importance of native SM, and possibly NSILA-S, under physiological conditions lies in its 
growth promoting effect and much less if at all in its insulin-like (i.e. primarily glucose 
and fat metabolism regulating) character. The latter may be uncovered only after 
realizing a direct contact with certain target organs in vitro. In addition, the effect may be 
further magnified by extraction, either by removing inhibitory substances or by dissociating 
it from its aggregated form or from a carrier. Comparison of native and purified SM with 
regards to their binding characteristics should resolve this issue. Somatomedin appears to be 
of fundamental importance and its anticipated availability in clinical practice holds great 
promise. However, only in vivo experimentation with this substance, both in its native 
and its purified form will provide definitive answers as to its role in physiology and 
pathology. 
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SUMMARY 
In this thesis our own and collaborative work on somatomedin is reported and related to 
the data from the literature. The introduction stresses the complexity of growth regula~ 
tion and the important role which hormones play in it. Amongst them, growth hormone 
and the supposed mediator if its effect, somatornedin, take a central position. 
The experiments which led to the discovery of 'sulfation factor' (somatomedin) by 
Salmon and Daughaday are described in chapter one. 
Ozapter two summarizes our studies on this substance. Attempts to characterize it 
(section A) led to the following conclusions. In native plasma it is macromolecular. 
Certain extraction procedures reduce its apparent size drastically, suggesting either 
disaggregation or release from a carrier. By electrofocusing a major peak of activity at 
pH 6.6 ~ 6. 7 and a minor one at pH 5.2 were found. Separation of plasma into a fraction 
which stimulates sulfation and another stimulating DNA replication was never obtained. 
Somatomedin behaves like a peptide. 
The distribution of 12 5 I~growth hormone shortly after intravenous administration to 
young rats, suggested the liver and possibly other organs as the source of somatomedin 
(section B). 
Section C mentions the motivation for changing the name from sulfation factor to 
somatomedin. 
A method for measuring somatomedin in vitro, using porcine rib cartilage is described in 
section D. It has the advantage of being highly precise and easy to perform. However, it is 
less sensitive than the hypophysectomized rat assay. 
Section E reports on experiments designed to investigate possible species differences, 
similar to those described for growth hormone. Plasma from 7 mammalian species had a 
sornatomedin-like effect on the cartilage of rat, pig, monkey and man, suggesting that the 
specificity of growth hormone exists at the level of somatomedin generation rather than 
in the specificity of the somatomedin produced. 
Section F describes the dose~response relationship between exogenous growth hormone 
and plasma SM in two hypopituitary children. It also demonstrates the high degree of 
correlation between plasma SM and total urinary hydroxyproline excretion in these 
patients throughout the ·studies. In four children, considered to be either partially growth 
hormone deficient or 'normal delayed',varying responses were obtained, irrespective of the 
endogenous growth hormone secretion. Nevertheless, the overall correlation between SM 
and OH-proline remained fairly good. 
A case of sornatomedin deficiency is reported in section G. This patient has high plasma 
levels of endogenous immunoreactive growth hormone, which by electrofocusing and 
immunologically appears to be normal. Both during shortterm and chronic growth 
hormone administration a blunted response was found with respect to all indices of 
growth hormone action, including SM generation, suggesting an overall and specific 
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non-responsiveness to the hormone. It is thought that the deficiency of SM is the cause of 
his short stature. 
In Chapter three the current knowledge of somatomedin is reviewed. It can be sum-
marized as follows. 
It seems well established now that somatomedin is the transmitter of the growth 
promoting effect of growth hormone. Its origin is probably the liver. Other organs such as 
muscle, kidney and possibly others are also suspected to produce it. It circulates in blood 
apparently in large molecular form. When purified under dissociating conditions it 
behaves like a peptide with a molecular weight between 4,000 and 8,000 daltons. In terms 
of its molecular characteristics it is very similar if not identical to NSILA-S. It has a 
longer half-life than growth hormone. Somatomedin appears to be less species specific 
than growth hormone. 
Plasma levels can now be determined with a precision, sufficient for quantitative studies. 
They increase up to the age of six years and remain relatively constant thereafter. There 
are no sex differences. Plasma SM is low in hypopituitarism and its levels are restored by 
growth hormone treatment. There is a quantitative relationship between exogenous GH 
and plasma SM-levels on one hand and the endogenously produced SM and hydroxy-
proline excretion on the other. Children have been reported, presenting with the clinical 
picture of hyposomatotropism despite high immunoreactive plasma growth hormone 
levels. They have low SM-levels. It is thought that somatomedin deficiency is the cause of 
their short stature. 
In other disorders of growth and nutrition, SM is sometimes unexpectedly low such as for 
example in dysmorphic dwarfism and surprisingly also in young children with cerebral 
gigantism. In obesity it is normal in spite of low plasma GH. In contrast, in malnutrition, 
where GH is normal or high, plasma SM is very low. The metabolic effects of SM, as 
inferred from in vitro experimentation with either native plasma or purified extracts is 
qualitatively similar to insulin: it stimulates protein and RNA synthesis, and DNA 
replication in muscle and cartilage. In cartilage it also stimulates sulfation of chondroitin, 
the synthesis of the protein moiety of the mucopolysaccharide-protein complex as well as 
the conversion of proline into collagen OH-proline. Semi-purified SM fractions stimulate 
glucose consumption in fat cells and suppress epinephrine induced lypolysis. Similar 
partially purified SM-preparations seem to compete with insulin for the same receptor 
sites on fat cells, chondrocytes and liver cell membranes. Both the biological effect of 
somatomedin on cartilage and its binding affinity to chondrocytes are much more 
important than its effects and binding to fat cells when compared to insulin. The 
physiological importance of somatomedin in carbohydrate and fat metabolism is uncer-
tain. Its fundamental role in the control of growth seems much better established .. 
Nevertheless, only in vivo experimentation can furnish the definitive proof. 
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SAMENVATTING 
Dit proefschrift beschrijft ons onderzoek over somatomedine (SM) en vergelijkt de 
resultaten met de gegevens uit de literatuur. In de inleiding wordt de complexiteit van de 
regulering van groei belicht en de belangrijke rol welke hormonen hierin spelen. Groeihor-
moon en somatomedine, dat geacht wordt het groeistirnulerende effekt van groeihormoon 
op de weefsels over te dragen, bezetten een centrale plaats. 
De experimenten die geleid hebben tot de ontdekking van 'sulfation factor' (somatome-
dine) door Salmon and Daughaday worden in hoofdstuk een samengevat. 
In hoo.fdstuk t1vee wordt het eigen onderzoek over somatomedine beschreven. 
Pogingcn om somatomedine te karakteriseren (section A), leidden tot de volgende con-
clusie. In plasma is het hoog moleculair. Sommige extractie procedures reduceren zijn 
moleculaire groottc in belangrijkc mate. Dit maakt het waarschijnlijk dat SM in plasma in 
geaggregeenle vorm voorkomt of aan een dragerrnolecuul gehecht is. Electrofocusering 
sp[itstc de aktiviteit in cen grote fraktie met een pH van 6.6-6.7 en een kleinere met een 
pH van 5.~. l\1ct gcen enke!e technick kon plasma gescheiden worden in een fraktie die de 
sulfatcring en een andere die de DNA-replikatie stimuleert. Somatomedine gedraagt zich 
als een peptide. 
In scctie B wordt beschrcven hoe de lokalisatie van 12 5 1-groeihormoon kort na intra-
veneuzc toediening aan jonge rat ten, de lever en mogelijke andere organen als potentiCle 
bron van somatomedine aanwezen. 
In section C wordt de motivering aangcgeven die geleid heeft tot het veranderen van de 
naam 'sulfation factor' in somatomedine. 
Onzc methode voor het me ten van somatomedine in vitro, die gebruik maakt van varkens-
ribkraakbeen, is beschreven in sec tie D. Deze methode is nauwkeurig en eenvoudig, maar 
minder gevoelig dan deze waarin het kraakbeen van hypophyseloze ratten wordt gebmikt. 
Sec tic E heschrijft expcrimenten die erop gericht waren een eventuele diersoort specifici-
teiL gclijkaardig aan deze van grocihormoon op te sporen. Plasma van zeven verschillende 
mammalia had een somatomedine-achtig effekt op het kraakbeen van de rat, het varken, 
de aap en de mens. Dit wijst erop dat de specificiteit van groeihormoon tot stand komt bij 
de inductie v~m somatomedine en niet in de interaktie van het geproduceerde SM met de 
weefscls. 
Hct 'dosis-response' vcrband tussen toegedicnd groeihormoon en plasma SM bij twee 
kindcrcn met hypophysaire insufficientie wordt beschreven in sec tie F. Ongeacht de dosis 
grocihormoon hleek er een zeer goede korrelatie te bestaan tussen plasma SM en de 
uitscheiding van hydroxproline met de urine. Bij vier kinderen die hetzij als partieel groei-
hormoon deficient hetzij als 'nonnaal klein' gcklassificeerd waren, werden veranderingen 
van het plasma SM waargenomen die niet korreleerden met de endogene groeihormoon 
sekrctie. De korrelatie tussen SM en hydroxyproline was ook bij deze kinderen goed. 
In sectie c; wordt cen tc klein kind met somatomedine deficientie beschreven. Deze 
jongen heeft een hoge plasma koncentratie van immunoreaktief groeihormoon, dat noch 
door electrofocuseren noch op immunologische grand van normaal groeihonnoon kan 
worden onderscheiden. Langdurige behandeling met groeihormoon gaf nauwelijks enig 
effekt te zien. Dit gold een grote reeks indices, waaronder het plasma SM gehalte. Het 
gebrek aan groei van dit kind moet vermoedelijk aan zijn somatomedine deficientie 
worden toegeschreven. 
Hoofdstuk drie geeft een overzicht van de huidige kennis over somatomedine, waaruit 
hieronder de belangrijkste aspekten worden gelicht. 
Het blijkt nu vrijwel zeker dat somatomedine het groeistimulerende effekt van groei-
hormoon op de weefsels overdraagt. Het wordt waarschijnlijk in de lever gesynthetiseerd. 
Het is niet uitgesloten dat ook andere organen, zoals denier en de spier deze stof zouden 
kunnen synthetiseren. Het circuleert in het bloed als een hoog moleculaire verbinding. Na 
is6Iatie onder dissocierende omstandigheden gedraagt het zich als een peptide met een 
moleculair gewicht tussen 4000 en 8000. De moleculaire eigenschappen gelijken sterk op 
die van NSILA-S (non suppressable insulin like activity - soluble fraction). 
Somatomedine heeft een langere halfwaarde tijd in het bloed dan groeihormoon. Het is 
minder diersoortspecifiek dan groeihormoon. 
Plasma gehaltes kunnen nu gemeten worden met voldoende nauwkeurigheid om kwanti-
tatieve studies toe te Iaten. Er zijn aanzienlijke leeftijdsverschillen in het normale 
plasmagehalte aan somatomedine. Tot de leeftijd van zes jaar is er een stijging waarna een 
relatief; konstant niveau behouden blijft. Er is geen verschil tussen beide sexen. Het 
plas~a gehalte aan sematomedine is laag bij patienten met hypophysaire insufficientie en 
wordt tijdens behandeling met groeihormoon genormaliseerd. Er is een dosis afhankelijk 
verband tussen de hoeveelheid toegediend groeihormoon en plasma somatomedine bij 
groeihormoon deficiente kinderen. Bij deze patienten is er een uitstekende korrelatie 
tussen plasma somatomedine en de totale hydroxyproline uitschreiding in de urine. 
Bij sommige patienten, die het klinische beeld van hyposomatotropisme vertonen, terwijl 
ze toch hoge plasma groeihormoon waarden hebben, werd een laag somatomedine gehalte 
gevonden. Het gebrek aan somatomedine is vermoedelijk de oorzaak van hun trage groei. 
In andere pathologische toestanden, zowel bij groei- als bij voedingsstoornissen zijn de 
somatomedine waarden soms afwijkend. Zo is het gehalte laag bij dysmorphische kinde-
reo met korte gestalte, doch ook bij jonge kinderen met het zgn. cerebrale gigantisme. In 
obesitas, waar plasma groeihormoon laag is, is somatomedine normaal. Bij kinderen met 
ondervoeding is het laag, terwijl het plasma groeihormoon normaal of verhoogd is. 
De metabole effekten van somatomedine werden tot op heden bijna uitsluitend in vitro 
bestudeerd met somatomedine bevattend plasma of na gedeeltelijke isolering ervan. De 
gevonden effekten zijn kwalitatief te vergelijken met die van insuline: het stimuleert 
eiwit- en RNA-synthese, alsmede DNA-replikatie in spier en kraakbeen. In kraakbeen 
stimuleert het de sulfatering van chondroitine, de vorming van de mucopolysaccharide-
-eiwit complexen en van collageen. Gedeeltelijk gezuiverde extrakten hebben eveneens 
effekt op het koolhydraat en vetmetabolisme: de glucose konsumptie van vetcellen wordt 
erdoor gestimuleerd en de lipolyse wordt geremd. 
Eveneens met gebruikmaking van gezuiverde frakties is aangetoond dat somatomedine in 
6! 
kompetitie is met insuline voor dezelfde bindingsplaatsen op de plasma membranen van 
vetcellen. chondrocyten en levercellen. In kwantitatief opzicht heeft somatomedine een 
veel grotere bindingsaffiniteit voor kraakbeen dan insuline. Hetzelfde geldt voor het 
biologische effekt van beide stoffen op dit weefsel. Ten aanzien van de vetcelliggen deze 
verhoudingen omgekeerd. 
De fysiologische betekenis van somatomedine in de regulering van het koolhydraat- en 
vetmetabolisme is onzeker. Zijn fundamentele rol bij het reguleren van groeiprocessen is 
veel overtuigender aangetoond. Toch zijn in vivo experimenten nodig om het definitieve 
bewijs ervan te leveren. 
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ADDENDUM 
Paper 1. Reprinted from ACTA ENDOCRINOLOGICA, 66: 65-81, 1971 
PARTIAL CHARACTERIZATION OF SULPHATION 
AND THYMIDINE FACTORS IN ACROMEGALIC PLASMA 
By 
]. L. Van den Brande'', ]. ]. Van W yk, R. P. Weaver 
and H. E. Mayberry 
Departments of Pediatrics and Anatomy, University of North Carolina, 
Chapel Hill, N.C., USA 
Department of Paediatrics, School of Medicine, 
Rotterdam, The Nether lands 
ABSTRACT 
This study was undertaken to characterize further the growth hormone 
dependent plasma factors which stimulate sulphate uptake (PSF) and 
thymidine incorporation (PTF) in cartilage segments from hypophysecto~ 
mized rats. 
An assay system utilizing labelling with 35SQ4 and 3H-methyl-thymidine 
was devised to measure both types of activity simultaneously and to 
determine whether these activities run in parallel during chemical frac-
tionation procedures. 
Acromegalic plasma stimulated sulphate and thymidine uptake as much 
as 18 X and 80 X respectively above the uptake of the basal medium. 
Activity measurements were not rigidly quantitative due to high variances, 
especially in PTF measurements. 
Both activities in acromegalic plasma were thermo-labile at 80°C for 
SO minutes. PSF was stable from pH 2- pH 10. PTF was possibly par-
tially inactivated at pH 2. Digestion with pronase destroyed PSF and 
probably PTF. Acromegalic plasma was fractionated by graded ethanol 
precipitation, ion exchange chromatography, starch gel electrophoresis, 
and molecular sieving through Sephadex (G-100, G-200). PSF and PTF 
activities run in parallel throughout these procedures. These findings 
Supported by a research grant to J. L. V dB. from Human Growth, Inc., a Cancer 
Re~earch Grant (to J.J. VW.) from the Elsa U. Pardee Foundation, and the following 
grants from the U.S. Public Health Service: Research Grant AM01022, Training 
Grant AM05330, and Career Research Award K6AM14, 115 (].]. VW.). 
* Present address: Department of Pediatrics, School of Medicine, Sophia Children's 
Hospital and Neonatal Unit, Rotterdam, The Netherlands. 
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suggest that the active material is associated with a peptide with a mole-
cular weight between 9500 and 35 000, which is more positively charged 
than many other plasma proteins. 
The incorporation of radioactive sulphate into the chondroitin sulphate of 
growing cartilage can be readily demonstrated either by administering 35S04 
to the animal in vivo (Dziewiatkowski et al. 1949; Dziewiatkowski 1951) or by 
incubating pieces of cartilage in vitro (BostrOm & Mansson 1952) in a nutrient 
medium containing the isotope. Ellis et al. (1953) demonstrated that sulphate 
incorporation in vivo is at least partially growth hormone (GH) dependent, 
since it is reduced by hypophysectomy, and partially restored by the in vivo 
administration of GH. Salmon & Daughaday (1957) showed that the in vitro 
incorporation of 35SO, into rib cartilage from hypophysectomized (hypox) rats 
is stimulated by the presence in the medium of serum from normal rats or from 
hypophysectomized rats which had been treated with GH, but not by serum 
from untreated hypophysectomized rats. The addition of growth hormone to 
the medium in concentrations up to 50 ,uglml had strikingly little effect. The 
results of 35S04 uptake studies using plasma from acromegalies, normal human 
subjects, and from hypopituitary patients before and during GH-treatment 
have been similar to those obtained in the animal experiments (Daughaday 
et al. 1959; Almqvist 1960, 1961; Almqvist et al. 1961; Almqvist & Falkheden 
1961). 
Using similar techniques the incorporation of :3H-methyl thymidine as well 
as the conversion of proline into hydroxyproline have likewise been shown to 
be partially GH dependent (Daughaday & Mariz 1962; Daaghaday & Reeder 
1966; Murakawa & Raben 1968). In vitro incubation of cartilage from hypox 
rats with normal serum increases hydroxyproline conversion and thymidine 
incorporation, whereas serum from hypox rats is either inactive or has an in-
hibitory effect. It has not been demonstrated, however, whether the thymidine 
incorporating activity (PTF) in the serum of hypox rats can be restored by the 
administration of growth hormone. Experimental evidence demonstrating the 
growth hormone dependence of PTF and thus completing the parallelism with 
plasma sulphate incorporating activity (PSF), has been collected by the present 
authors, and will be the subject of a separate report. 
Synthesis of chondroitin sulphate and collagen are representative of the dif-
ferentiated biosynthetic capacities of cartilage tissue, whereas the incorporation 
of thymidine into DNA is characteristic of cellular proliferation. There is 
reason to believe that growth is a reflection of both phases. Since these events 
do not occur synchronously within the cell cycle, it seemed of importance to 
ascertain whether the plasma factor which influences sulphate uptake by car-
tilage tissue (PSF) is the same as that which influences thymidine uptake 
(PTF). 
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An in vitro assay using a dual isotope labelling technique was developed to 
measure both PSF and PTF simultaneously. The assay was used to characterize 
both factors in acromegalic plasma, and to study their stability. 
MATERIALS AND METHODS 
The assay technique described by Daughaday & Reeder (1966) for 3H-methyl-thymidine 
incorporation was modified by the addition of 35SQ4 to the incubation medium and 
by the revision of other minor procedural details. 
Male Sprague-Dawley rats were hypophysectomized through the parapharyngeal 
route at the age of 25 days1l and ust:d 12-15 days later in the assay. On arrival in 
our laboratory,· they were fed pulverized laboratory chow ad libitum and 5 G/o sucrose 
in their drinking water until sacrifice. The animals were killed with ether. Body and 
gonadal wei!;hts were then obtained. If either of these findings suggested incomplete 
hypophysectomy, the sella was examined under a dissecting microscope. Animals with 
pituitary remnants were discarded. 
Using an aseptic technique the extraneous tissue was removed from the costal car-
tilage of the Srd through the 9th ribs. One to three cartilage segments approximately 
4 nim in length were obtained from each rib. Segments closer than 2 mm to the 
costochondral junction were discarded. 
Each segment was incubated in a glass vial containing 0.6 ml of incubation medium 
and covered by loosely fitting metal or glass caps. Each plasma sample or fraction 
to be assayed was incubated in sextuplicate with one piece of cartilage from each of 
six rats. Cartilage segments from the same animal were distributed at random among 
the samples to be assayed. The concentration of plasma or fraction in the medium 
was at most 16.7 Ofo (v/v). 
The incubation medium differed from that used by Daughaday & Reeder (1966) 
only by the addition of 100 ,ug/ml of kanamycin. The medium was prepared from 
frozen stock solutions on the day of the assay and filtered through a 0.45 ,u Milli-
pore filter before. 
The incubation was carried out in air in a Dubnoff metabolic shaking incubator at 
37°C and at 60 r. p.m. After 24 h, I ,uCi Na.235SOll and/or 3H-methyl-thymidine2l 
in 50 pi of incubation medium was added to each vial, and the incubation was con-
tinued for another 24 h. 
At the end of the incubation the pieces of cartilage were placed between sheets of 
filter paper in individual plastic tissue washing capsules and immersed in boiling 
water for 3-5 min. They were then washed for 4-6 h in running tap water. Control 
incubations with heat killed cartilage revealed that this procedure reduced non-
incorporated radioactivity to negligible values. 
The washed pieces of cartilage were air dried for at least 16 h and weighed on a 
Cahn electro-balance to the nearest microgram. It was found that the weight became 
constant after a few hours of exposure to ambient air. The standard error among 
1 ) Hormone Assay Laboratories, Chicago, Illinois. 
2) 3H-methyl-thymidine with a specific activity of > 10 Ci/mM was obtained from 
Schwarz Bio Research Inc. Carrier free Na235SQ4 was obtained from Cambridge 
Nuclear Corp. 
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replicates was less when the radioactive uptake was related to the dry weight than 
when related to the weight of protein in the cartilage. 
The cartilage segments were digested in liquid scintillation vials containing 0.6 rol 
of 90 '(1/n formic acid. The vials were covered with glass marbles and placed in a 
boiling water bath for SO to 40 min with periodic vigorous shaking. Some small 
threadlike particles were still present at the end of the digestion. More prolonged 
digestion, however, resulted in a loss of 3H, possibly by exchange and evaporation. 
The liquid scintillation cocktail had the following composition: Toluene/triton X-100 
(3/1, vlv), 0.6 g/100 m1 PPO, and 0.02 g/100 m1 dimethyl-POPOP. To increase 
counting stability, 4 g/100 ml thixotrophic gel (Cab-0-Sil) was added. Radioactivity 
of the sample plus 15 ml of cocktail was measured in a Packard liquid scintillation 
counter. Correction for quenching was made by the sequential addition of internal 
standards and recounting. 14C-Benzoic acid was used to correct for quenching of 35S 
and 3H-palmitic acid for the quenching correction of 3H. 
Reference standard and starting material for the fractionation 
Heparinized or citrated plasma from two adult patients with active acromegaly was 
used for the standard curves and as the starting material for further fractionation. 
The activity of PSF and PTF in unknown samples was computed from log dose 
response curves of the reference plasma or a semi-purified derivative of this run 
simultaneously. The term plasma equivalents (pl. eq.) indicates the original volume 
of plasma in ml from which a given sample is derived. Protein concentrations were 
measured by the Lowry method (Lowry et al. 1951). 
Fractionation of acromegalic plasma 
Fractionation procedures were carried out at 0---4°C and the specimens to be assayed 
were stored at -20°C. 
(a) Ethanol precij;itation at neutral j;Ji. Ethanol was added with vigorous shaking 
over a 2 min period to whole acromegalic plasma until a 20 °/n (v/v) concentration 
was reached. After standing overnight and centrifugation, an aliquot of the super-
natant was raised to a 40 °/o (v/v) concentration. Finally, the ethanol concentration 
of an aliquot of the 40 °/n supernatant was raised to 80 °/o (v/v). The biological 
activity remaining in the respective supernatant fractions was assayed in aliquots 
which had been lyophilized and re-dissolved in water to the plasma volume from 
which they were originally derived. 
(b) AdsorfJtion to DEAE and CM cellulose. The 20·0Jo ethanol supernatant was fur-
ther fractionated with pre-swollen microgranular dietylaminoethylcellulose (Whatman 
DE-52) and carboxymethyl cellulose {Whatman CM-52). The cellulose was equilibrated 
by washing five times with 10 volumes of the selected buffer. In batch experiment~, 
1.0 pl. eq. of the sample was intermittently shaken with 1 g of absorbant for 1 h. 
After centrifugation, the supernatant was filtered over glasswool and lyophilized. The 
non-adsorbed material remaining in the supernatant after exposure to DEAE cellulose 
equilibrated with 0.01 M ammonium bicarbonate buffer pH 8.5 is referred to hereafter 
as >,DE-material<<. 
For gradient elution column chromatography on DEAE, the sample was applied in 
0.01 M ammonium bicarbonate buffer pH 8.5. The material retained on the column 
was then eluted with ammonium acetate buffer in a pH gradient from pH 6.55 to 5.0 
and an ionic gradient from 0.01 to 0.1 M. 
(c) Molecular sieving. Both acromegalic plasma and >>DE-material« were fractionated 
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on Sephadex G-100 and G-200. The Sephadex was thoroughly washed with demine-
ralized water (at least 10 times the bed volume). This abolished the inhibitory. effect 
of concentrated eluates on the assay. The eluant was 10 times diluted Krebs' phospho-
saline buffer pH 7 .4. 2 ml fractions were collected, pooled into portions according 
to the elution pattern (0. D. read at 280 nm), lyophilized, and re-dissolved in de-
mineralized water. They were then dialyzed twice for 2 h against 250 volumes of a 
Krebs phosphosaline buffer. 
(d) Starch gel electrophoresis. The technique was carried out as described by 
Smithies (1959). Hydrolyzed starch (Connought Laboratories) was used at a concen-
tration of 10.3 <Jfo. The electrode buffer was NaOH 0.06 M, H 3B03 0.3 M, pH 8.5. The 
gel buffer was NaOH 0.0104 M, H 3B03 0.026 M, pH 8.4. The origin was placed in the 
middle of the plate. One lateral slot was filled with human serum stained with brom-
phenol blue. The remaining slots were filled with a total of 2.0 pl. eq. of »DE-
material« and electrophoresed at 4°C for 5 h (300 V with 25 rnA). 
After electrophoresis, the lateral margins of the plate were cut, stained with amido-
black, and used as a guide for the division of the remainder of the plate. The gel 
was frozen, thawed, and cut transversely in 9 zones. The fluid was expressed from 
each zone by compression in a syringe stoppered· with a glasswool plug. The fluid 
was then lyophilized, redissolved in a smaJl volume of water, dialyzed, and assayed 
at a concentration of 0.21 °/o (plasma equivalent in medium). 
Stability of the biological activity 
(a) Exposure to heat. 1.0 pl. eq. aliquots of DE-material in 1.5 ml of a Krebs phos-
phosaline buffer were exposed for 30 min in a shaking waterbath to temperatures of 
40, 50, 60, 70, or 80°C. The incubation was terminated by abruptly cooling the samples 
in ice. 0.1 ml aliquots of the supernatants were assayed after centrifugation. 
(b) Exposure to varying pH. Under constant pH and volume monitoring, 1.0 pl. eq. 
aliquots of ))DE-material« in 3 mi of water were slowly titrated at 4°C to pH 2, 4, 
6, 8, or 10 by the addition of 0.02 N NaOH or 0.02 N HCI. Once the desired pH was 
reached, the sample was allowed to stand for 6 h at 4°C. The pH was then slowly 
readjusted to 7.4. The samples were lyophilized and redissolved in 1.5 ml with water 
and 0.1 ml of this solution was added to each incubation flask in the assay. 
(c) Enzymatic hydrolysis. To 0.5 pl. eq. of the 20 °/o ethanol supernatant, 0.5 ml of a 
solution containing 3 mg/ml Pronase3) was added. The sample was sequentially in~ 
cubated for 24 h at 37°C, heated for 30 min at 70°C, cooled in ice, and centrifuged. 
To remove the Pronase the supernatant was adsorbed to DEAE-cellulose by the batch 
method described above. Two parallel controls were run. Control one (C1) was in~ 
cubated without Pronase to monitor losses not due to enzymatic action. ln. control two 
(C.2) the biological activity was added immediately before the assay to check the 
effectiveness of Pronase removal. 
RESULTS 
The bioassay 
The standard log dose response curves for thymidine and sulphate incorpora-
tion in four consecutive assays are shown in Fig. 1. In these assays, which were 
3) Pronase: Streptomyces Griseus protease, B grade, lot 34045, Calbiochem, Los An-
geles, 45000 P. U.K. unit/g. 
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Dose-response curves of in vitro 35S04- and 3H-thymidine incorporation into hypox rat costal cartilage. 
Assay No. 19-20: Plasma from a patient with active acromegaly. 
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Values for 1 No. 19 35S: 0.36, 3H: 0.56. 
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typical of many others, the lambda values for sulphate uptake ranged between 
0.!9 and 0.70 and for thymidine uptake between 0.34 and 0.56. There were 
also unexplained deviations from linearity. Although rigorous attempts were 
made to standardize the assay procedure the variances between replicates re-
mained distressingly large. This was particularly true for 3H-thymidine in-
corporation, although the greater steepness of the slopes partially compensated 
for the larger variances. Since lambda values greater than 0.4 preclude precise 
quantitation, the present results should. be considered as semi-quantitative 
estimations of potency (Emmens 1962). 
Two way analyses of variance in numerous assays revealed that for both 
PTF and PSF the variance not accounted for by preparation differences was 
in general divided about equally between the variance between rats and the 
residual variance due to all other factors. An analysis of factors which might 
possibly contribute to the intercartilage variation was therefore carried out by 
multiple regression analysis of an experiment in which 2 dose levels of »DE-
material« were assayed against medium. Five cartilage segments from each of 
6 rats were incubated with each dose level of DE-material. The variables 
tested were the differences between rats, rib number, location of cartilage seg-
ment within the rib, length/weight ratio, curvature, completeness of cleaning 
extraneous tissue, smoothness of the cartilage surface (reflecting trauma to the 
perichondrial membrane), and completeness of digestion in formic acid. These 
variables were graded by arbitrary codes. 
The factors contributing significantly to the intercartilage variance are in 
parallel for 3580.1 and 'H-thymidine incorporation (Table 1). Apart from the 
variance due to differences between the preparations, the result was also in-
fluenced by the length/weight ratio, the smoothness of the surface and the 
curvature of the cartilage fragment. The possible meaning of these findings 
will be discussed below. 
Fractionation of acromegalic plasma 
(a) Ethanol precipitation at neutral pH (Fig. 2). Starting with the 20 'io 
ethanol concentration, a progressive loss of both PSF and PTF activity occurred 
in the supernatant fractions with increasing ethanol concentration. No biolo-
gical activity was detectable in the supernatant fractions after precipitation 
with 80 'io ethanol. 
(b) Adsorption to ion exchangers. In a preliminary experiment using only 
35804 uptake as a measure of activity, whole plasma was exposed in batch to 
CM 52 and DE 52 at different conditians of pH and ionic strength. After 
centrifugation, the degree of adsorption was determined by comparing the 
biological activity remaining in the supernatant fluid with that in the original 
plasma. Biological activity was recovered in the supernatant fraction from 
DE-52 only with ammonium bicarbonate 0.01 M, pH 8.5 (Table 2). 
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Table 1. 
Multiple regression analysis of factors contributing to the intercartilage variation. 
Length:weight ratio 
Smoothness of the surface 
of the cartilage fragment 
(damage to perichondrial membrane) 
Curvature 
Incubation medium with 
no addition 
0.5 °/o human plasma (FP) 
2.0 Ofo 
Mean 
Intercept 
Data are expressed as log DPMimg cartilage. 
length/weight: Mean: 3.4 7. 
Code 
I 
2 
s 
I 
2 
3 
3H-
35S04 Thymidine 
1.63 1.59 
1.65 0.44 
3.28 0.87 
4.92 !.31 
-0.91 -0.31 
-1.82 -0.13 
-2.13 -1.10 
-2.62 -0.80 
-O.I9 -0.16 
2.82 0.96 
4.60 2.o7 
-4.IO 0.38 
Damage: code I to 3 corresponds to increasing raggedness of the surface of the tissue. 
Curvature: The fragments of cartilage most curved after drying obtained the highest 
code. 
The low total protein concentration remaining in this fraction suggests that 
the biologically active material is positively charged relative to many other 
plasma proteins. This interpretation is consistent with the findings after ad-
sorption to carboxymethyl cellulose at pH 5.0. Under these conditions most or 
all of the biological activity was adsorbed, whereas there was relatively less 
adsorption of other plasma proteins. 
These findings were further explored by applying a 20 o;o ethanol super-
natant preparation to a DE 52 column and eluting with 0.01 M ammonium bi-
carbonate buffer at pH 8.5 (Fig. 8). A large amount of biological activity, both 
PSF and PTF, was recovered with the single protein peak eluted. Another 
DEAE column eluted with a decreasing pH and an increasing ionic gradient 
showed that most, if not all, of the biological activity was present in the first 
protein peak (Fig. 4). Attempts to recover the biological activity adsorbed on 
CM-52 were unsuccessful. 
(c) Molecular sieving. From preliminary experiments utilizing Sephadex 
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Fig. 2. 
Ethanol precipitation of human plasma. Biological activity of the supernatants at 20. 
40, and 80 °/o ethanol concentration. 
Experimental details: see material and methods. 
Protein concentrations of the fractions: 
Starting plasma: 62.6 mg/ml pl. eq. 
20 °/o ethanol-supernatant: 48.0 
40 Ofo 38.0 
80 °/o 0.16 
G-1 00 the biological activity in whole plasma was shown to be associated with 
the macromolecular fraction. After fractionation of }}DE-material« on a large 
column of Sephadex G-200 (Fig. 5) biological activity was recovered in a 
fraction with Kav-values between 0.58 and 0.85. The total protein content of 
this fraction was 0.62 mg as compared to 21.6 mg of the sample. 
(d) Vertical starch gel electrophoresis. PSF and PTF were recovered from 
both the fractions comprising the origin and the adjacent anodal area (Fig. 6). 
In addition some PSF-activity was also present in the fraction closest to the 
anode. 
Stability of the biological activity 
(a) Thermal and pH stability. Fig. 7 illustrates that all biological activity 
was abolished after exposure to 80°C. Exposure to a pH range from 2 to 10 
did not affect the PSF activity, whereas PTF was diminished by exposure to 
a pH of 2 (Fig. 8). 
(b) Stability to enzymatic proteolysis. Many attempts to perform enzymatic 
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Table 2. 
Recovery of PSF activity from acromegalic plasma after batch adsorption by DEAE 
cellulose pH 8.5, 0.01 M and CM-celluose pH 5.0, 0.01 M. The residual biological 
activity remaining in the respective supernatant fractions after adsorption was assayed 
at a concentration of 16.7 (pl. eq.) 0/o. 
Incubation medium 
Plasma (McBr) 1.67 °/o 
3.3 °/o 
6. 7 Ofo 
Conditions of adsorption: 
CM-52 NH4Ac. 0.01 M. pH 5 
DE-52 NH,HCO, 0.01 M, pH 8.5 
103 DPM 35S/mg 
±sEM 
16 ± 7 
48 ± 12 
65 ± 16 
106 ± 28 
18 ± 4 
15 ± 16 
protein concentration 
in incubation medium 
mg/ml 
0 
1.2 
2.4 
4.8 
6.7 
0.7 
proteolysis failed because of the difficulty in separating the enzyme from the 
biological activity. Although both PTF and PSF activities were regularly lost 
after exposure to the enzyme, activity was retained in both controls only when 
the previously described method was used for removing the Pronase from the 
active fraction before assay. The results conclusively demonstrate that PSF 
activity is destroyed by enzymatic proteolysis (Fig. 9). This is probably also 
true for PTF activity, but the high variance encountered in one of the controls 
makes this conclusion less certain. 
DISCUSSION 
An assay system which permits the simultaneous measurement of sulphation 
and thymidine incorporating activities, affords many advantages in comparing 
the influence of substances affecting skeletal growth. The present technique 
for measuring sulphation factor differs from previously described systems in 
that a 24 h period of pre-incubation preceded the addition of 35SQ4. This pre-
incubation is required for assessing stimulation of thymidine incorporation 
(Daughaday & Reeder 1966) but may adversely affect the precision in measuring 
sulphation factor activity. 
The great variability between costal cartilage segments is for the most part 
intrinsic to the use of this tissue as the test object. Metabolic activity at the 
costochondral end is much higher than elsewhere (Y de 1968). This can be 
circumvented by discarding the distal portions. When the remainder of the 
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Chromatography on DEAE-cellulose. Elution with NH4HC03 0.01 M at pH 8.5. 
Starting material: 2 pl. eq. of human plasma derivate (200/o ethanol supernatant). 
Column specifications: 
dimensions 23.5 X 0.6 em 
flow rate : 3.18 mVh 
fraction volume: 1.9 ml 
Assay: without further processing 5.3 °/o of total fraction volume per incubation 
flask. 
rib was divided, we found no systematic variation between the lateral and 
medial segments. However, the striking influence of the length to weight ratio 
(Table 1) reflects a lack of uniformity in response between thick and thin 
segments. Radioautography of cartilage segments after incubation reveals that 
cell division occurs primarily beneath the perichondrium and in the peripheral 
zones rather than in the inner shaft. The responses should therefore more 
appropriately be related to surface area (were this measurable) than to weight. 
85 
O_Q_ at 2 BO nm 
20 
1.6 
0.9 
'·' 
--" 
___ .mMho PH mHho 
6.5 4 
./ . ./·-·-·- 6.0 3 
s.s 2 
/ ------------ 5.0 1 
-·-·-·-·-·- _..,... 
I I I I • 
FRACTIONNUMSER 
Fig. 4. 
Gradient elution chromatography on DEAE-cellulose. 
Starting material: 2 pl. eq. of human plasma derivative (20 Ofn ethanol supernatant). 
Column specifications: 
dimensions 18.7 X 0.6 em 
flow rate 3.4 ml/h 
fraction volume: 0.67 ml, pooled according to elution pattern. 
Assay: Pooled fractions were concentrated on UM-3 ultrafilter (Diaflow) and washed 
twice with 5 volumes of demineralized water. 
Amount assayed: Fractions I, 4, 5, and 6: 5 Ofa, fraction 2: 2 °/o, and fraction 3: 10 O/o 
of the total pooled fraction volume per incubation flask. 
Fraction 1 is the basal uptake with medium alone. 
The influence of curvature is less well explained. The effect of raggedness of 
the surface of the cartilage tissue might be considered as an attempt towards 
repair by the release of tissue »chalones« (Bullough !967). Although the net 
effect of these influences precludes strict quantitation of assay results, the 
activities observed were sufficiently large to obtain useful information. 
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Fig. 5. 
Molecular sieving on Sephadex G-200. 
Starting material: 3 pl. eq. of human plasma derivate (»DE-material«). 
Column dimensions: Vt: 410 ml, Vo: 144 ml 
Flow rate : 11.5 mUh, reversed flow. 
Eluent : 1/10 Krebs-phosphosaline-buffer. 
Fractions of 2.3 ml were pooled according to elution pattern. 
Assay: l/10 of each pooled fraction per incubation flask. 
Progress in isolating and characterizing the GH dependent plasma factors 
which stimulate cartilage growth has been slow. Koumans & Daughaday (1963) 
demonstrated PSF activity in the macromolecular fraction eluted from Sep-
hadex G-25, although it was not established whether the active material was 
a peptide. Ferguson et a/. (1968) subjected plasma from acromegalic subjects 
to gel filtration and starch gel electrophoresis and found >>a number of acidic 
proteins with growth promoting activity«. 
The present studies were undertaken to define further the chemical nature 
87 
·A·"ItlHf!l!llll&" WHOLE HUMAN 
neg_ pole- ri -,-r--r-ri,j:tJ!I-.. IIw~T"III""'--r-, PLASMA 
SAME AF"TER 
OEAE ADSORPTION dpm35sJ 
7mg cartilage 
f ORIGIN 
'" 
dpm3H/ 
3 /rng cartilage 
'"I ::1 ]:=JE:i::Ji~!jj~;~m=J=J~~El 
Fig. 6. 
Starch gel electrophoresis of »DE-material«. 
Experimental details-: see text. 
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Fig. 7. 
Heat stability of the biological activity. 
Starting material: human plasma after adsorption to DEAE-cellulose. 
Experimental details: see text. 
of the active substances, using as starting material plasma from patients with 
active acromegaly. Incubation of active fractions with Pronase destroyed PSF 
activity and probably PTF activity, thus suggesting that a molecule with pep-
tide linkage is necessary for the biological effect. The thermal inactivation 
curve is consistent with this conclusion. 
The lack of binding to DEAE-cellulose at pH 8.5 and at low buffer ionic 
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Fig. 8. 
pH-stability of the biological activity. 
Starting material: human plasma after adsorption of DEAE-cellulose. 
Experimental details: see text. 
strength and the minimal movement in starch gel toward the anode at pH 8.4, 
suggest that the active molecule is slightly basic relative to other plasma pro-
teins. This conclusion is consistent with the somewhat selective adsorption of 
PSF to CMC cellulose at pH 5.0. 
The progressive loss of biological activity with increasing concentration of 
ethanol at neutral pH suggests that the active material is of large molecular 
weight. Chromatography on Sephadex G-200 suggests a molecular weight in 
excess of 9500 and less than 35 000 (Andrews 1966), although the fractions 
were not cut finely enough to allow a more precise estimation. The experiments 
reported here do not reveal whether the active material itself has a large 
molecular weight or whether it is a smaller molecule bound to a protein 
carrier. 
PSF and PTF run in parallel throughout the procedures except with regard 
to their stability at pH 2.0. However, subsequent studies have revealed that 
both PSF and PTF can be extracted from acromegalic plasma by acid ethanol 
extraction (Van W yk et al. 1969). Whether or not these activities represent 
the same or different molecular species must await further steps in purification. 
Such studies are in progress in our laboratories. Progress in the isolation and 
characterization of these materials, however, will remain slow until a simpler 
and more accurate assay system is developed. 
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pH-stability of the biological activity. 
Starting material: human plasma after adsorption of DEAE-cellulose. 
Experimental details: see text. 
strength and the minimal movement in starch gel toward the anode at pH 8.4, 
suggest that the active molecule is slightly basic relative to other plasma pro-
teins. This conclusion is consistent with the somewhat selective adsorption of 
PSF to CMC cellulose at pH 5.0. 
The progressive loss of biological activity with increasing concentration of 
ethanol at neutral pH suggests that the active material is of large molecular 
weight. Chromatography on Sephadex G-200 suggests a molecular weight in 
excess of 9500 and less than 35 000 (Andrews 1966), although the fractions 
were not cut finely enough to allow a more precise estimation. The experiments 
reported here do not reveal whether the active material itself has a large 
molecular weight or whether it is a smaller molecule bound to a protein 
carrier. 
PSF and PTF run in parallel throughout the procedures except with regard 
to their stability at pH 2.0. However, subsequent studies have revealed that 
both PSF and PTF can be extracted from acromegalic plasma by acid ethanol 
extraction (Van Wyk et al. 1909). Whether or not these activities represent 
the same or different molecular species must await further steps in purification. 
Such studies are in progress in our laboratories. Progress in the isolation and 
characterization of these materials, however, will remain slow until a simpler 
and more accurate assay system is developed. 
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Further Purification and Characterization of Sulfation 
Factor and Thymidine Factor from Acromegalic Plasma 
JUDSON J. VAN WYK, KERSTIN HALL, J. LEO VAN DEN BRANDE, AND 
ROBERT P. WEAVER 
Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina 27514, Department of 
Endocrinology and Metabolism, Karolinska Sjukhuset, Stockholm, Sweden, and Department of Pediatrics, 
School of Medicine, Rotterdam, The Netherlands 
ABSTRACT. The chemical characteristics of 
sulfation factor (PSF) and thymidine factor 
(PTF) have been studied in whole acromegalic 
plasma and in acid ethanol (AE) extracts of 
plasma. In whole plasma PSF and PTF are ex-
cluded by the XM-100 ultrafiltration membrane 
and behave as large proteins. After extraction 
with acid ethanol the mol wt appeared to be 
>3900 ~ 12,400, suggesting that in native plasma 
PSF and PTF are either aggregated or bound to 
a larger carrier protein. Two species of peptides 
with PSF and PTF activity were found. Chroma-
tography of whole plasma on DEAE-cellulose 
revealed a major peak of biologic activity which 
was not adsorbed at pH 8.5 and a smaller com-
ponent which was adsorbed at pH 8.5 but eluted 
at pH 5.5. Electrofocusing of AE extracts re-
vealed a sharp minor peak at pH 5.2 and a 
broader major peak at pH 6.6-6.7. The possi-
bility that the more acidic component may be 
P REVIOUS studies have suggested that the plasma sulfation factor (PSF) and 
plasma thymidine factor (PTF) in human 
plasma from normal or acromegalic sub-
jects are either proteins or bound to a pro-
tein carrier (1-4). Similar inferences have 
been made for the sulfation factor in 
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due to insulin cannot be excluded. HV electro-
phoresis of a purified AE extract revealed activity 
only in the neutral zone. Chromatography of an 
AE extract on CMC-cellulose at pH 5.6 in a 
linear ionic gradient between .01 and 0.40M re-
sulted in the recovery of PSF and PTF in a 
small protein peak well separated from the bulk 
of other proteins. Rechromatography of the 
CMC eluate on Sephadex G-50 yielded a prep-
aration with an increase in specific activity over 
native plasma of 6200 X for PSF and 15,000 X 
for PTF. This discrepancy probably reflects the 
removal of inhibitors having a greater effect on 
thymidine incorporation, since no separation of 
PSF from PTF was observed in any system. If a 
provisional molecular weight of 8000 is assumed 
and no allowance is made for residual contam-
inants, the purest preparation is highly active at 
3.1 X10- 8 molar concentration. 
normal beef and rat plasma, and in plasma 
from hypophysectomized rats after treat-
ment with growth hormone (5, 6). In 
previous publications we have reported on 
some characteristics of this substance (or 
substances) in acromegalic plasma and 
have demonstrated that PSF and PTF 
can be extracted in good yield with an acid 
ethanol reagent (4, 3). The present paper 
provides further details of the physical 
characteristics of this material in native 
plasma and in acid ethanol extracts as 
revealed by ion exchange chromatography, 
gel chromatography, ultrafiltration, high 
voltage paper electrophoresis and iso-
electric focusing. By using a combination 
of these techniques, two components of 
PSF and PTF activity have been demon-
strated and the major component partially 
purified. 
Materials and Methods 
Blood was removed from fasting acromegalic 
patients, the plasma separated and stored at 
-20 C until use. A pool of plasma from several 
untreated acromegalic patients was heated in a 
Dubnoff shaker at 56 C for 30 min, stored for 15 
hr at 4 C, and then centrifuged at 2500 rpm. 
This procedure did not alter the biologic ac-
tivity and preserved the linearity of responses 
at higher dosage levels. The supernatant was 
lyophilized, except for small aliquots which were 
stored at -20 C for use as reference standards 
in the biologic assay. In the subsequent purifica-
tion procedures and biologic assays the tenn 
"plasma equivalents" (pl.eq.) is used to indi-
cate the original volume of plasma in ml from 
which each preparation was derived. Dosage in 
the assays is expressed as pl.eq. %; e.g., 75 
pl.eq. % means that an aliquot ultimately 
derived from 0.75 ml of original plasma was 
represented in 1.0 ml of incubation medium. 
Acid ethanol extraction. The lyophilized plasma 
was suspended and homogenized at 4 C in 1 j 4 
to 1/6 of the original plasma volume of 0.1M 
NH, acetate (pH 6.8). The homogenates were 
vigorously shaken for 30 min at 4 C with 3 vol 
of acid ethanol reagent (48 ml ethanol:l ml 
concentrated HCl) and then centrifuged at 
10,000 Xg for 30 min (7). The precipitate was 
resuspended once in NH4 acetate, re-extracted 
with the acid ethanol reagent, washed twice in 
water, and re-extracted with acid ethanol. The 
residual precipitate was discarded. 
The supernatants were combined, brought to 
pH 8.0-8.4 with N aOH and filtered on a 
Buchner funnel through Whatman #1 filter 
paper. The filtrate was cooled to -10 C and 
added in a fine stream with stirring to 4 vol of 
prechilled acetone-ethanol mixture (5 :3 v jv). 
After 12-24 hr at -10 C the precipitate was 
collected by aspirating most of the supernatant 
and centrifuging the remainder. The clear 
yellow supernatant was discarded. The white 
precipitate was resuspended in a small amount 
of cold acetone-ethanol (5 :3 v jv), and then 
centrifuged at 4000 X g. The liquid phase was 
decanted and the precipitate was air dried. 
Thereafter the precipitate was dissolved in 
.05M NH,HCO,, pH 8.5. The insoluble material 
remaining after centrifugation was washed 
twice more with NH4HC03• The supernatants 
were combined and the insoluble material dis-
carded. 
Wtrafiltration. Sixty ml of frozen plasma was 
thawed, filtered through a Millipore filter, and 
added to the chamber of a model 52 ultrafiltra-
tion cell (Amicon Corp., Lexington, Mass.) con-
taining a UM 05 membrane. When the volume 
was reduced to about 1/3, the original volume 
was restored with glass distilled water and the 
filtration repeated. This process was repeated 4 
times. The total filtrate was lyophilized and the 
retentate removed by repeated washing and 
then passed successively in similar fashion over 
XM-50 and XM-100 filters. Aliquots for assay 
were removed at each step. Other studies were 
performed in a similar fashion starting with 
XM-100 filter and passing the respective 
filtrates through successively smaller pore 
filters. All operations were carried out at 5 C 
using nitrogen as the pressure source. 
Gel chromatography. Ascending gel chromatog-
raphy was performed at +4 C through 
columnsofSephadex G-100, Sephadex G-50 and 
Sephadex G-25 (fine) equilibrated with O.Ol-
0.06M NH,HCO, (pH 8.5). The columns were 
calibrated with dextran blue (2 X 10" av. mol 
wt), bovine serum albumin (69,000 mol wt), egg 
albumin (45,000 mol wt), chymotrypsinogen 
(25,000 mol wt), cytochrome C (12,400 mol wt), 
B chain of insulin (3900 mol wt) and N aCl 
(located by conductivity measurements). The 
plasma fractions and marker samples were 
applied in NH,HCO, (.Ol-.05M) and eluted 
with the same solution. After determining the 
UV absorbance, the individual fractions were 
pooled into larger fractions and lyophilized prior 
to assay. 
Anion exchange chromatography. A chromato-
graphic column 20 X2 em was packed with pre-
swollen rnicrogranular diethylamine cellulose 
(Whatman DE-52) which had been equilibrated 
with 0.01M NH,HCO,, pH 8.3. To this was 
applied 10 ml of plasma. The column was 
developed by stepwise elution with O.OlM 
NH,HCO.,, pH 8.53, 0.05M NH, acetate, pH 
6.2, and O.lM NH, acetate, pH 5.0. 
Cation exhange chromatography 
Dowex 50. Chromatography on Dowex 50 
WX2 (200-400 mesh)H+ was carried out on a 
column with bed. volume of 50 ml at a flow rate 
of 2 ml/min. The resin was washed with 0.06M 
acetic acid, pH 3, until the pH of the effluent 
was equal to that applied.. Samples were dis-
solved in ! bed volume of 0.6N acetic acid. 
Elution was carried out successively with 3 bed 
volumes of .06N acetic acid, demineralized 
water, 0.15M NaCl and .05M NH.,OH. This was 
followed by 9 column volumes of 0.2M NH,OH. 
Carboxymethyl cellulose. For chromatography 
on carboxymethyl cellulose, a column measur-
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ing 1.2 X 13 em was packed with pre-swollen 
microgranular carboxymethyl cellulose (CM-
52) which had been equilibrated and extensively 
washed with 0.01M NH, acetate, pH 5.6. The 
sample to be applied was diluted in NH4 
acetate, pH 5.6, and further diluted with water 
until the conductivity matched that of .01M 
NH, acetate (0.60 mho). The total volume was 
pumped through the colmnn and the column 
then washed with an equal volume of .01M NH4 
acetate, pH 5.6. The column was then eluted 
with 500 ml NH4 acetate, pH 5.6, in a linear 
molar gradient between .01 and 0.40 molar. 
Electrofocusing. An LKB 8102 ampholyne 
column (440 ml) was used. LKB ampholyte 
with a pH range from 5 to 8 was used at a final 
concentration of 1 %. Sucrose gradients were 
made either by hand or with an LKB gradient 
mixer. The 2 solutions for the gradient were 
composed as follows: A) 100 g sucrose, 3.75 ml 
40% ampholyte pH 5-8, and 150 ml water; B) 
1.25 ml 40% ampholyte and 215 ml water. 
Acid ethanol extracts, 8 pl. eq. in one experi-
ment and 20 pl.eq. in another, were propor-
tioned between the 2 gradient solutions. The 
anode buffer consisted of 48 g sucrose in 56.0 ml 
0.33N HBO, and the cathode buffer consisted 
of 40 ml of 2.5N NaOH. Approximately 300 V 
was applied until the current was stable for 12 
hr. The total duration of equilibration was 94 
hr. The column was drained at a rate of 12 
ml;'hr into a fraction collector and the optical 
density read at 280 m,u. The pH was monitored 
in every fifth fraction. The fractions were stored 
at -20 C and then diluted in incubation 
medium for biological assay. A control column 
without added biologic material was run in 
identical fashion. 
High voltage electrophoresis. The lyophilized 
sample was dissolved in a minimum amount of 
acetate buffer, pH 6.5, and applied as a band to 
a sheet of Whatman 3 MM paper with about 
1.0 mg of dried sample/em. High voltage 
electrophoresis was then performed in pyridine 
acetate buffer, pH 6.5, at 60 V /em for 50 min 
by the procedure of Ryle et al. (8) in a modified 
apparatus of Michl (9). A guide strip of the 
dried paper was cut and stained with ninhydrin-
cadmium acetate. Ninhydrin positive bands 
were cut from the paper, eluted by 0.05N 
NH40H, and lyophilized. An aliquot was saved 
for assay and the remainder applied to a second 
strip for electrophoresis at pH 2.0. 
Polyacrylamide gel electroplwresis. Electrophore-
sis was carried out in glass tubes (6 mm i.d.) at 
5 C according to the method of Davis (10) in gel 
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concentrations of 7.5% pH 8.9. The proteinE 
were fixed in 7% acetic acid and stained with 
ami do black or fixed in 12!% trichloroacetic 
acid and stained with Coomassie blue. 
Protein determination. Protein measurements 
were made by one or more of the following 
methods: Lowry's modification of the Folin 
Ciocalteau method (11), ninhydrin determina-
tion after alkaline hydrolysis (12), and by the 
difference in absorbance at 215 and 225 ml' (13). 
Studies with ["'1] insulin and ["'1] HGH. 
Human growth hormone (HGH) and insulin 
were iodinated with 131I according to the method 
of Hunter and Greenwood (14) and purified by 
vertical starch gel electrophoresis (growth hor-
mone) or Sephadex G-75 (insulin). The specific 
activities were approximately 540 mCijmg 
(HGH) and 435 mCi/mg (insulin). Purity was 
checked by chromatoelectrophoresis in the 
presence and absence of antibody excess. 
Approximately 1 X 10' cpm of each of the 
labeled hormones was added to separate ali-
quots of 20 ml of normal human plasma after 
the plasma had been lyophilized and resus-
pended in O.lN NH4 acetate. Acid ethanol ex-
tracts were prepared which were then passed 
over Dowex 50 H+ and eluted as described 
above. The recovery of radioactivity was deter-
mined by counting a1iquots in the weB of a 
gamma spectrometer. 
Immunoassay of insulin and growth hormone. 
The growth hormone and insulin content of 
starting plasma and certain plasma fractions 
were determined by radioimmunoassay by a 
modification of the double antibody technique 
(15).' 
Bioassay procedure. Biologic activity was deter-
mined in vitro by 3 different systems. Most 
preparations were assayed by a system using 
costal cartiJage segments from hypophysecto-
mized male rats and dual labeling with 3&SQ4= and 
[ 3H-methyl] thymidine to assess simultaneously 
the incorporation of sulfate and thymidine. 
This method is a modification of the technique 
described by Daughaday and Reeder (16) and 
has been previously described (4). Some prepa-
rations were assayed for su1fation factor activity 
by the embryonic chick pelvic leaflet method 
described by Hall (17). The fractions derived 
from the electrofocusing column were assayed 
for PSF and PTF activities by a method using 
1 Human growth hormone was Wilhelmi HS 968 
C furnished by the National Pituitary Agency. 
Purified pork insulin assaying at 25.9 mU jmg, Lot 
818194, was a gift of the Eli Lilly Co. 
:ostal cartilage segments from a single normal 
>repubertal rhesus monkey (to be published). 
rhis assay technique is approximately 1/10 as 
ensitive as the assay utilizing cartilage from 
1ypophysectomized rats but is advantageous in 
.erms of simp1icity. 
In scanning a large number of fractions for 
>iologic activity, results axe expressed as %in-
:rease in uptake of the respective isotopes above 
he basal uptake by cartilage segments when 
ncubated in medium alone. Since the slope and 
ensitivity varied from assay to assay and was 
lifferent for thymidine and sulfate uptake, such 
·esults provide inadequate estimates of poten-
:ies. Quantitative estimates of recovery and 
JOtency, where given, were determined on an 
.BM 1130 computer by a program which 
tppJies tests of validity and assesses potency 
atios and 95% fiducial limits from symmetrica] 
Our- or six-point bioassay designs (18, 19).2 
{esults were discarded if deviations from 
>arallelism or linearity were significant (p > .05). 
['he precision of the assays expressed as A 
•aried between 0.20 and 0. 75. 
~ioassay of PSF and PTF with anti-insulin and 
~nti-human growth hormone antibodies. To deter-
nine whether any portion of the biologic ac-
ivity assayed as PSF and PTF could be ac-
:ounted for by growth hormone or insulin, an 
tcid ethanol extract of acromegalic plasma was 
tssayed at 3 dosage levels in the presence of both 
mti-HGH and anti-insulin antisera, respec-
ively. The antisera were each present in a 
:oncentration of 1:5000.3 
2 This computer program accepts sample weights, 
pecimen dosages and raw counting data from per-
orated paper tape. Efficiency corrections are made 
JY either the internal or external standard method. 
l'he calculated dpm/mg for both isotopes is stored 
•n a magnetic disc to be recalled later for com-
Jarisons between any 2 preparations in the same 
Lssay. Variances are determined by 2-way and 1-
vay analyses of variance in the rat and chick em-
Jryo assays, respectively. In 4-point assays con-
rasts between preparations are assessed for 
ignificant differences between activities in the 
;ssay and significant deviations from parallelism. 
n 6-point assays, significant deviations from 
inearity and significant opposite curvature are 
Llso assessed. The statistical treatment of results 
:; based on formulae for orthogonal coordinates 
lescribed by Finney (18) and Borth (19). This 
1rogram is available on request (J.J.V.W.). 
3 In a 1:1,000,000 dilution, the HGH antisera 
10und 50% of growth hormone when present in a 
oncentration of0.2 ngjml. In a dilution of1 :85,000, 
he insulin antiserum bound 50('~ of the insulin 
vhen the latter was present in a concentration of 
; .uU /ml. These determinations of antibody po~ 
Results 
I. Properties of PSF and PTF in native 
acromegalic plasma 
Ultrafiltration. When native acromegalic 
plasma was passed successively through 
the UM-05 and XM-50 filters, the biologic 
activity was quantitatively recovered in the 
respective retentates, whereas the filtrates 
were totally inactive (Table 1). When the 
:){M-50 retentate was passed through the 
XM-100 membrane, most of the PSF and 
PTF activity was again found in the re-
tentate. Stimulation of thymidine incor-
poration by the filtrate was not significant, 
although the filtrate was possibly slightly 
active in stimulating sulfate incorporation 
(p = .05). Similar results were obtained 
with single passage of whole plasma 
through filters of differing porosity. 
According to the manufacturer (Amicon 
Publication #403), 95 °{ of bovine serum 
albumin (mol wt 67 ,000) in dilute solution 
is fully retained by the XM-50 membrane, 
whereas only 45% of this substance is re-
tained by the XM-100 membrane. It is 
possible, however, that in the presence of 
whole plasma the effective pore size may 
have been reduced below these putative 
limits. 
Chromatography on Sephadex. When acro-
megalic plasma was applied to Sephadex 
G-25, 62% of the PSF activity was re-
covered in the peak of excluded protein 
(Fig. 1). Succeeding fractions caused slight 
stimulation of sulfate uptake in the chick 
assay but in the rat assay no activity was 
discernible after the major protein peak. 
In similar studies with more precise quanli-
tation, the recovery of both PSF and PTF 
in the major protein peak regularly ex-
ceeded 75% of the activity in native 
plasma. 
Anion exchange chromatography. In ac-
cordance with previous findings ( 4), when 
tency were carried out by incubating in verona! 
buffer at pH 8.6 for 6 days at 5 C, whereas the 
assays for PTF and PSF in the presence of the 
respective antisera were carried out for 48 hr at 
37 C in Krebs phosphosaline buffer. pH 7 .4. 
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TABLE 1. Ultrafiltration of acromegalic plasma 
Retent. XM-50 
Active 
Acromegalic plasma UM 05 
----< (frozen & thawed) 
Filt. 
Inactive 
Retent. XM-100 
Active 
Filt. 
Inactive 
Retent. 
Active 
Filt. 
Slightly 
Active (?) 
·---·--·------------------
Preparation 
Medium 
Plasma (K.W.) 
XM-100 
Retentate 
XM-100 
Filtrate 
Concentration % 
(pl. eq.) in medium 
0.75 
1.50 
3.00 
1.5 
3.0 
3.0 
12.0 
whole plasma was applied to DEAE-
cellulose in .01M NH.,HCO,, pH 8.5, most 
of the activity recovered appeared in the 
fall-through volume (43% for PTF and 
12 1\ for PSF) (Fig. 2). Unlike the earlier 
study, however, a small but significant 
amount of biologic activity was present in 
two adjacent fractions eluted with am-
monium acetate 0.1M, pH 5.0. The re-
covery of PTF in these fractions was 1.5 
and 3.1 <•.; •. For PSF the respective recovery 
figures were 2.1 and 1.1 %. The material 
eluted at acidic pH has not been further 
studied. In similar DEAE columns insulin 
has been quantitatively recovered in this 
regwn. 
II. Properties of PSF and PTF in the acid 
ethanol extract. Acid ethanol extraction of 
lyophilized acromegalic plasma has now 
been performed many times with recoveries 
of both PSF and PTF activities in the range 
of 30-40%. The reason for this Joss of 
activity is not clear, but it may be due to 
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dpm/mg S( of Uptake in Medium ( ±SEM) 
Thymidine Sulfat~ 
100 ± 13 100 ± 7 
46-l± 53 223 ±11 
508 ± 56 277 ±18 
574± 43 264 ±10 
495 ± 65 232 ±13 
561 ± 103 251 ± 10 
115± 34 123 ± 9 
111 ± 21 136 ± 7 
physical trapping or protein: protein inter 
actions in the bulky precipitate. Dose 
response curves for acid ethanol extract 
parallel those of whole acromegalic plasm 
(Fig. 3). The protein content (11) of thes 
extracts has varied between 0.1 and 0.: 
mg per plasma equivalent. The biologi. 
activity per mg of protein has varied be 
tween 60 and 225 times greater than i1 
native plasma. 
Chromatography of acid ethanol extrac 
on Sephadex G-100. When an acid ethano 
extract containing 100 pl.eq. was appliec 
to a column of Sephadex G-100, both PSI 
and PTF activities were recovered in th• 
fractions preceding the elution volume fo 
NaCl and well separated from the bulk o 
proteins in the ethanolic extract (Fig. 4) 
The peak was recovered at a molecula1 
weight corresponding to that of cytochrom• 
C (mol wt 12,400), but some biologic ac 
tivity was also eluted in the lower molec 
ular weight fractions which followed. B) 
summing the biologic potencies in th< 
O.D. 
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10 ml 
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::J 300 15 
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CHICKEN ASSAY lL 
0 
~ 
:;; 
::J 
15 600 w 
THYMIDINE UPTAKE :;; 400 lL 
RAT ASSAY 0 i: 
200 
:;; 
::J 300 0 
SULFATE UPTAKE w 200 :;; 
RAT ASSAY lL 0 100 
~ 
_ _!>l_E J~~-
~_!' ~U_M_ 
----
Sephodex G-25 2.5 x 80cm 
0.06M NH4HC03 pH 8.4 
-----
100 200 
EFFLUENT ml 
300 400 
Frc. 1. Ascending gel chromatography on Sephadex G-25 in 0.06M NH4HCOJ, pH 8.4. Ten ml acromegalic 
plasma was applied to the column (2.5 X80 em). Absorbance was measured at 230 m,u. Before biological 
assay, individual fractions were combined into pools as indicated by vertical lines. The unstarred fractions 
were obtained from the same column and assayed at a concentration of 12% (0.12 pl.eq./ml). The starred 
fractions were obtained from another column and assayed at a concentration of 6 %. Bars represent mean 
uptake of 35804 - and [3H-methyiJthymidine expressed as percentages relative to the mean uptake of 
cartilages incubated in basal medium alone. The mean and sEM were derived from 6 replicate determina-
tions. 
active fractions, over-all recovery values 
from native plasma were estimated as 21% 
for PTF and 11% for PSF. Accurate pro-
tein measurements and a more precise 
bioassay of the combined active fractions 
could not be carried out since some of the 
protein became insoluble after the second 
lyophilization. 
Cation exchange chromatography on car-
boxymethyl cellulose. Five hundred pl.eq. 
of a pool of active fractions derived from 
three acromegalic donors was applied to a 
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FIG. 2. Clu·omatography on DEAE~cellulose. T~n ml acromegalic plasma was applied to a column (2 X20 
em) in O.Ol~M NH 4HC0 3, pH 8.5, and thereafter eluted stepwise as shown with O.OlM NH 4HC0 3, pH 8.5, 
0.05M NH 4 acetate, pH 6.2, and O.lM NH4 acetate, pH 5.0. Fractions of 4 ml were collected. After mea-
suring the absorbance at 254 m,u the fractions were combined into pools as indicated by vertical lines. The 
conventions described under Fig. 1 were used in plotting data. The uptakes shown for the first peak were 
obtained at 2% concentration (pl.eq. in medium), whereas those in the second peak were obtained at a 
16 ~;-~, concentration. 
CMC column. Some of these fractions 
were crude acid ethanol extracts, whereas 
others had been further purified on Dowex 
50 and Sephadex G-100. After being dis-
solved in NH, acetate, pH 5.6, and diluted 
with water until the conductivity matched 
that of .OlM NH, acetate (0.60 mho), the 
total volume was 420 ml. This volume was 
pumped through the column and the 
column then washed with another 420 ml 
of NH, acetate, pH 5.6. The column was 
98 
further developed in a linear ionic gradient 
between .01 and 0.40 molar. Under these 
conditions, most of the proteimiceous ma-
terial passed through the column without 
adsorption and was biologically inactive. 
Biologic activity was recovered only in a 
small protein peak which was eluted be-
tween .025 and .15M concentrations (Fig. 
5). The two most active fractions together 
contained 10 l'g protein/pl.eq. (11, 13) 
and accounted for 57% of the PTF ac-
"' Q 
125 ~: 
100 
ACID ETHANOL EXTRACT (AE 11 l 
vs 
ACROMEGALIC PLASMA(LF.) 
THYMIDINE UPTAKE 
b~ 46,650 
)."' .69 
POTENCY 
RATIO 95%Ft0l.ICJALUMITS 
IN ASSAY .75 .35-1.49 
FINAL .37 .IS- .75 
25 
20 
., 
Q 
~ 
SULFATE UPTAKE 
),:0: .31 
POTENCY 
RATIO 95% FIDUCLALUMITS 
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FINAL .31 .22-.41 
5 ----------11!....~-------------
0.125 0.25 1.00 2.00 8.00 16.00 0.125 025 
CONCENTRATION "!. 
1.00 2.00 a.oo 16.oo 
FIG. 3. Dose response curves obtained with an acid ethanol extract compared with the acromegalic 
plasma from which it was derived. Uptakes of 35804- and [JH-methyl]thymidine are expressed in dpm/mg 
dry cartilage. Each point represents the mean of 6 cartilages (1 from each of 6 rats) and the brackets indi-
cate ±SEM. Potency ratio "In Assay" refers to relative responses in the assay irrespective of dose. "Final" 
potency ratios reflect the relative activities of the 2 preparations adjusted for the dosages used in thf'. 
assay. 
tivity applied to the column. The over-all 
recovery of PTF in these fractions, when 
assayed against acromegalic reference plas-
ma, was about 10%. The assays for PSF 
were roughly similar, but did not meet 
statistical criteria. Since the pool applied 
to the column was composed in part of 
acid ethanol extracts which had previously 
been purified by other methods, the sources 
of loss cannot be accurately identified. 
Adsorption to glass surfaces and incomplete 
recovery from chromatographic columns 
are common occurrences in peptide frac-
tionation, however, and may account for 
important losses during PSF and PTF 
purification. 
The electrophoretic pattern of the active 
CMC fractions in acrylamide gel was con-
trasted with that of starting plasma and an 
acid ethanol extract (Fig. 6, C). A major 
peptide band migrating with the front and 
at least three fainter bands of more re-
tarded protein are visible in the CMC 
preparation. Larger quantities of protein 
would undoubtedly have revealed even 
greater heterogeneity. 
Chromatography of CMC fractions on 
,Sephadex G-50. The three fractions with 
biologic activity from the carboxymethyl 
cellulose column were pooled, lyophilized, 
and an aliquot equivalent to 175 pl.eq. was 
applied to a column of Sephadex G-50. 
The elution pattern of proteins disclosed 
considerable heterogeneity (Fig. 7). The 
biologic activity was eluted between the 
cytochrome C marker (mol wt 12,400) and 
the insulin B chain marker (mol wt 3900). 
The protein content of the most active 
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FIG. 4. Ascending gel chromatography on Sephadex G-100 in O.OlM NH4HC0 3, pH 8.5. One hundred pl. 
eq. of acid ethanol extract in a volume of 5 ml was applied to the column (2.5 X98 em). Fractions of 4.8 
ml were collected at a flow rate of 30 ml/hr. After measuring the absorbance at 215 m,u the fractions were 
pooled for assay as indicated by the vertical lines. The conventions used in plotting data are given under 
Fig. 1. 
fraction was 0.26 l'g/pl.eq. (12, 13). This 
fraction contained 5.3% of the original 
PTF activity in native plasma and 2.2% 
of the original PSF activity, yielding an 
over-all purification of about 15,000 X for 
PTF and 6200 X for PSF. 
Cation exchange chromatography on Dowex 
50 H+. Studies of the chromatographic 
behavior of AE extracts on Dowex 50 
were undertaken because tills resin had 
100 
been successfully used to separate insulin 
from nonsuppressible insulin-like activity 
in plasma (20, 21). Using the procedure 
described in Materials and Methods, no 
biologic activity was recovered until 1! 
column volumes of 0.2N NH.,OH had passed 
through the column. The biologic activity 
was then eluted in a broad band with no 
separation from insulin and very little 
separation from other proteins. Although 
0.0. 
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FIG. 5. Chromatography on CMC-cellulose. Fiv(hundred pLeq. of acid ethanol extract was applied to 
the column (1.2 X13 em) in O.OlM NH4 acetate, pH 5.6, and washed extensively with the same buffer. 
Thereafter, the column was eluted in a linear gradient between 0.01 and 0.4M NH 4 acetate, pH 5.6. Frac-
tions of 10 ml were collected at a flow rate of 40 ml/hr and absorbancies were measured at 215 mJ.t. The 
fractions were pooled as indicated by the vertical lines and assayed for biologic activity. The conventions 
used for plotting results are described under Fig. 1. 
the recoveries in several experiments were 
almost quantitative, only a 2-fold purifica-
tion was achieved. 
Electrofocusing. Two different acid eth-
anol extracts were applied to an electro-
focusing column. In the first extract there 
was a sharp peak at pi 5.2 and a larger more 
diffuse peak at pi 6.6~6.8 (Fig. 8). In these 
studies, column eluates were dissolved 1:1 
(v jv) in incubation medium. In all frac-
tions the sulfate uptake was depressed be-
low control values although the relative 
values for sulfate incorporation in general 
paralleled the values for thymidine uptake. 
For this reason, dose response curves of two 
fractions (pH 5.0 and 6. 7) were compared 
with corresponding fractions from a con-
trol column run in an identical manner, 
but without added biologic activity. In 
these studies (Fig. 9), it became apparent 
that the concentration of eluate in the 
medimn had little effect on thymidine 
incorporation, but the incorporation of 
35804- was strongly affected, possibly due 
to isotopic dilution with inorganic sulfate. 
A second acid ethanol extract from the 
same patient but differing in protein con-
tent was applied to an electrofocusing 
column and the eluate assayed at a lower 
concentration in incubation medium. A 
sharp peak of both PSF and PTF activity 
was again seen at pH 5.2 and a broader 
peak with maximum at pH 6.7. 
High voltage electrophoresis. The active 
eluate from a Dowex 50 column was passed 
over Sephadex G-25. Biologic activity was 
found in a broad zone following the ex-
cluded protein peak. These active fractions 
were pooled and subjected to high voltage 
electrophoresis (HVE) at pH 6.5. The five 
ninhydrin positive bands were eluted, 
lyophilized, and tested for PSF activity in 
the chick assay. PSF activity in the chick 
assay was recovered only in the neutral band 
(Fig. 10). When this band was resubjected 
to HVE at pH 2.0, there was further 
!01 
resolution into four ninhydrin positive 
bands, but there was insufficient material 
for assay. No ninhydrin positive material 
was identified in the zone where the muscle 
sulfation factor described by Hall (22) 
migrates under similar conditions. 
II I. Studies with insulin and human growth 
hormone 
Immunoreactive growth hormone and insu-
lin levels. The immunoreactive growth 
hormone levels of the acromegalic plasma 
specimens used in these studies ranged be-
tween 20 and 30 ng/ml. The insulin con-
tent by radioimmunoassay ranged between 
38 and 62 .uU /mi. The recovery of immuno-
reactive insulin in several acid ethanol 
extracts was less than 50%. Levels com-
parable to those in acid ethanol extracts 
were recovered in the 0.2N NH,OH elu-
ate of Dow ex 50 H + and in a fraction 
eluted from DEAE at an acid pH. 
Studies with I'"'!] insulin and ["'!] 
HGH. The recovery of ['"'Il insulin and 
I'"' I I H G H in acid ethanol extracts was 
n.s and 54.3'';, respectively. When incu-
bated in the presence of an antibody excess 
of their respective antisera, 74.6% of the 
radioactivity from I'"I] insulin was pre-
cipitated and 79.5 ";, of the radioactivity 
from I"" I I HG H. When these extracts were 
passed over a Dow ex 50 H • column and the 
column developed as described previously, 
1""11 HGH was eluted slightly earlier than 
I'"' 1] insulin, but neither peak was sepa-
rated from the PTF and PSF activity. 
Assay of acid ethanol extracts in presence 
of anti-insulin and anti-HGH antisera. 
When an acid ethanol extract was assayed 
in antibody excess of anti-insulin and anti-
H G H antisera, respectively, there was no 
obvious inhibition of either PSF or PTF 
activity. In this assay, however, inhibition 
less than zoo.;, would not have been de-
tectable. 
Discussion 
Molecular size of PSF and PTF in whole 
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A B c 
FIG. 6. Polyacrylamide gel patterns of A) native 
plasma (.0025 ml), B) acid ethanol extract (0.5 
pl.eq.), C) a pool of the 2 most active fractions 
from the CMC column (5.0 pl.eq.) (Fig. 8). All 
were run at pH 8.9 in a gel concentration of 7.5 %. 
The amount of protein applied to each column 
was, respectively, A) 187.5 f..tg, B) 147 f..tg, C) 50 f..tg. 
A and B were fixed in 7% acetic acid and stained 
with amido black. C was fixed in 12 t% trichloro-
acetic acid and stained with Coomassie blue. 
plasma and in acid ethanol extracts. These 
ultrafiltration and gel chxomatography 
studies of whole acromegalic plasma sug-
gest that PTF and PSF are either large 
molecules themselves or are associated with 
a large protein. This conclusion has also 
been reached by. 'other workers (1, 2, 5). 
Bala et al. found that most of the PSF 
activity in normal and acromegalic plasma 
is eluted from Sephadex G-100 in a molec-
ular weight range similar to pituitary 
growth hormone (2). These results are at 
O.D. 
215 m}J 
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Sephadex G -50 2.5 x 91 em 
.01 M NH4HC03 pH 8.4 
EFFLUENT ml 
FIG. 7. Ascending gel chromatography on Sephadex G-50 in O.OlM NH 4HC0 3, pH 8.5. One hundred 
seventy-five pl.eq. (2.0 mg protein) of the 3 pooled and lyophilized biologically active fractions from 
CMC (Fig. 8) was applied to the column (2.5 X91 em) in a volume of 2 mi. Fractions of 10 ml were col-
lected at a flow rate of 30 ml/hr and absorbance was measured at 215 m,u. The fractions were pooled as the 
vertical lines indicate and assayed for biologic activity. The conventions used for plotting results are 
described under Fig. 1. 
variance, however, with the findings of 
Liberti (6) based on the ultrafiltration of 
bovine plasma. He found that sulfation 
factor activity in native bovine plasma 
behaves like a small molecule with a 
molecular weight on Sephadex G-15;;; 
5000. This discrepancy can be most rea-
sonably ascribed to species differences. 
The procedure of acid ethanol extraction 
was suggested to us by the successful 
employment of this technique to extract 
from organs and blood such biologically 
active peptides as insulin (23), nonsup-
pressible insulin-like activity (7, 20, 21), 
prolactin (24) and parathormone (25). 
After extraction of whole plasma with acid 
ethanol and chromatography on Sephadex 
G-50, PTF and PSF activity were re-
covered in fractions corresponding to a 
molecular weight range >3900;;; 12,400. 
The slope obtained with this material in 
the bioassay was identical with that ob-
tained with native plasma, suggesting that 
in whole plasma it might be either aggre-
gated or bound to a larger carrier protein. 
Purification of PSF and PTF by chromatog-
raphy on CMC-cellulose and Sephadex. 
Both Sephadex G-100 and CMC-cellulose 
proved highly efficient in separating PSF 
and PTF activities from the large mass of 
protein in ethanolic extracts. With the 
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()_.; hr. Eight pLl'q. of arid ethanol extract wa.-. 
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combined procedure of acid ethanol ex-
traction, cation exchange chromatography 
and gel chromatography we have purified 
PSF and PTF 6200 X and 15,000 X, re-
spectively, over their activities in native 
plasma. When present in a concentration 
of 250 ng protein 'ml, this preparation 
stimulated a 5.17 ( ± 1.4)-fold increase in 
thymidine incorporation and a 2.17 ( ± 
0.27)-fold increase in 35SO,~ incorporation. 
Asswriing a provisional molecular weight 
of 8000 and making no allowance for 
residual contaminants, the concentration 
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FIG. 9. Dose response curves ot fractions eluted 
from electrofocusing column at pH 5.0 and 6.7 
compared with dose response curves obtained with 
corresponding fractions from a control column. The 
dosages on the abscissa represent the concentration 
of eluate in medium (v /v). Eight pl.eq. of an acid 
ethanol extract was applied to the column. 
in this incubation calculates out to 3.1 X 
1o~s molar. This activity compares favor-
ably with other highly potent hormones. 
Relationship of PTF to PSF. In none of the 
fractionation procedures was it possible to 
separate PSF from PTF activity. The 
achievement of an apparently greater 
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FIG. 10. A. Amino acid markers after high voltage electrophoresis at pH 6.5. B. Ninhydrin staining spots 
after high voltage electrophoresis at pH 6.5 of an acid ethanol extract of acromegalic plasma after further 
purification on Dowex 50 and Sephadex G-25 (see text for details). C. Sulfation factor activity as measured 
in embryonic chick pelvic leaflets, in fractions eluted as shown with the- vertical lines. D. The active 
neutral zone was eluted and applied to the origin of another paper which was then subjected to high 
voltage electrophoresis at pH 2.0. Four ninhydrin positive spots were identified. Insufficient material was 
available for bioassay. E. Amino acid markers after high voltage electrophoresis at pH 2.0. 
purification of PTF. and the recovery from 
some columns of more activity than was 
applied, is most probably attributable to 
the removal of inhibitory substances. We 
have found such substances to be normally 
present in plasma and that they affect 
thymidine uptake more than sulfate uptake 
(3). Salmon et al. (26) also point out that 
whole serum from normal and hypophysec-
tomized rats contains material which is 
"toxic" for thymidine uptake in cartilage. 
Liberti observed that materials in bovine 
plasma which are inhibitory to sulfate 
incorporation can be removed by frac-
tionation through ultrafiltration mem-
branes (6). 
Evidence for at least two molecular species. 
Our results on anion exchange chromatog-
raphy of whole plasma and on electro-
focusing of acid ethanol extracts reveal 
that there is more than one active molecu-
lar species. Although only one of these 
species was identified on HVE, its mobility 
at both pH 6.5 and 2.0 suggests similar 
charge properties to the predominant pep-
tide (pi 6.6-6.8) found on electrofocusing. 
The behavior of the predominant com-
ponent on both anion and cation exchange 
resins is likewise consistent with a neutral 
peptide. 
The smaller peak of activity eluted from 
DEAE and from the electrofocusing 
column at pH 5.2 could conceivably have 
been due to the insulin content (pi 5.3) 
of the particular plasmas studied. Failure 
to detect this component after HVE might 
thus be explained since the chick assay 
is insensitive to insulin up to 8 mU /ml. 
Salmon has demonstrated that insulin 
stimulates both sulfate and thymidine 
uptake by rat cartilage, although the 
dose response curve is more shallow and 
maximal values are less than those ob-
tained with acromegalic plasma (5, 26). 
Unfortunately, these plasma samples are 
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no longer available for assay in the presence 
of anti-insulin serum. The lesser peak is 
slightly more basic than is human growth 
hormone. One of us (J.L.VdB.) has found 
that after electrofocusing HGH the peak 
found by radioimmunoassay appears at 
pH 4.9-5.0. 
It should be emphasized that our purest 
preparation is still heterogeneous and that 
yet other serum components with PSF and 
PTF activity may account for the losses of 
biologic activity sustained in the various 
purification steps. Nevertheless, since we 
have encountered no suggestion of biologic 
activity resident in protein fractions differ-
ing in size or charge properties from the two 
peptides or families of peptides described 
in this paper, we are inclined to believe 
that they represent most of the PSF and 
PTF activity found in human serum. Fur-
ther details of the molecular structure, 
origin and biologic actions of these sub-
stances are under study. 
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Early Localization of 1251-Labeled Human Growth Hormone in 
Adrenals and Other Organs of Immature Hypophysectomized Rats 
H. E. MAYBERRY, J. L. VAN DEN BRANDE, 1 J. J. VAN WYK, AND 
WILLIAM J. WAD DELL 
Departments of Anatomy and Pediatrics and Dental Research Center, University of North Carolina, Clwpel 
Hill, North Carolina 27514 
ABSTRACT. Human growth hormone (HGH) 
labeled with 1251 was injected intravenously into 
hypophysectomized, immature rats. One rat was 
frozen 6 min and another 20 min after injection 
by immersion in hexane cooled with dry ice. 
Whole-body sections were made of the frozen 
rats and autoradiograms were prepared by plac-
ing these sections on x-ray film. The autoradio-
grams revealed that, at both time intervals after 
injection, there was a high concentration of 
radioactive material in the kidney, liver and 
adrenal cortex. The only other tissues found to 
have a higher radioactive density than that of 
blood were the submandibular glands, nasal 
mucosa, gastric mucosa, bone and follicles of 
vibrissae. The radioactivity in the adrenal cortex 
was slightly higher in the zona glomerulosa than 
STUDIES of the distribution of tritiated and radioiodinated growth hormone 
(GH) in rabbits and guinea pigs and in 
hypophysectomized (hypox) and intact 
rats have revealed significant concentra-
tion of radioactivity in several organs, but 
in none of these studies was there signif-
icant localization of labeled material in 
epiphyseal cartilage (1-6). Concentration 
of radioactivity in the kidney and liver has 
been a constant finding, while varying re-
sults have been obtained concerning the 
concentration of radioactivity in muscle, 
fat, bone, pancreas, thymus, adrenals and 
spleen. 
Evidence is accumulating that GH does 
not act directly on epiphyseal growth, but 
rather stimulates the formation of secon-
Received March 30, 1970. 
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and AM-05330 from the NIH. 
Requests for reprints: Professor William J. 
Waddell, Dental Research Center, University of 
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1 Present address: University of Rotterdam 
Medical Faculty, Sophia Kinderziekenhuis, Rotter-
dam, The Netherlands. 
in the zona fasciculata and it was lowest in the 
zona reticularis. The concentration in the epi-
physeal plates was no higher than that in bone 
or soft tissues. The radioactivity in the sub-
mandibular gland had the electrophoretic mo-
bility of growth hormone and not free iodide. 
The distribution in 8 organs of 1311-albumin was 
compared with that of 1251-HGH at 6 and 20 
min by removal of the organs and direct isotope 
counting. The distributions substantiated the 
specific localizations of HGH seen in the auto-
radiograms. Pretreatment of the rats with 
ACTH or HG H 6 min before administering the 
1251-HGH altered the concentration of 1~:'1-HGH 
in kidney, liver and adrenals. (Endocrinology 
88: 1309, 1971) 
dary growth factors (sulfation factor and 
thymidine factor), which in turn stimulate 
the proliferation of epiphyseal chondro-
cytes and synthesis of cartilage matrix (7, 
8). The chemical identity and sites of pro-
duction of these secondary growth factors 
are unknown. In an attempt to obtain in-
formation regarding possible sites where 
skeletal growth factors are produced, the 
distribution of labeled G H was restudied 
with whole-body autoradiography in im-
mature, hypox rats. This technique was 
used so that all possible sites with increased 
affinity for growth hormone could be eval-
uated. These results were compared with 
results obtained by counting excised organs 
after the administration of 1251-human 
growth hormone and 1311-human serum al-
. humin. 
Materials and Methods 
Injected materials. 1251-labeled human growth 
hormone (I'"l-HGH)' was obtained from the 
!so-Serve division of the Cambridge Nuclear 
Corporation (lot 1088; SA 122 mCi/mg) and 
2 Originally obtained from Dr. A. E. Wilhelmi. 
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Abbott Laboratories (lot GH-080; SA 96 mCi/ 
mg). Purity was checked by electrophoresis on 
Whatman 3 MC paper utilizing veronal buffer 
0.05M, pH 8.6, with 600 V for 20 min at 4 C. 
After drying the strips at 90 C, the distribution 
of radioactivity was measured on a Baird 
Atomic strip scanner. Planimetric tracings were 
made to determine the percentages of radio-
activity in the zones migrating as protein and 
free iodide (9). 1311-human serum albumin 
(HSA) was obtained from Squibb (lot 52XM-
M18-500; SA 25 MCi/mg). Unlabeled human 
growth hormone was obtained from the NIH 
hormone distribution program (lot HS1182B).' 
ACTH was from Parke, Davis and Company 
(lot JF217). All solutions were injected in a tail 
vein. 
Animals. Male Sprague-Dawley rats3 were 
hypophysectomized at 25 days of age and used 
in the experiments 2~3 weeks later. In the 
studies in which the organs were removed for 
direct counting of radioactivity, completeness 
of hypophysectomy was determined by ex-
amination of the sella turcica and by the 
weights of the adrenals and gonads. Examina-
tion of the sella turcica and weights of the 
adrenals and gonads could not be used to de-
termine completeness of hypophysectomy in 
animals used for whole-body autoradiography. 
Extensive experience in our laboratory with 
similar rats, however, has shown that body 
weight correlates well with completeness of 
hypophysectomy; the present rats weighed no 
more than those of the same age in which 
hypophysectomy was proven to be complete. 
Whole-body autoradiography. Two rats were in-
jected with 10 MCi of "'I-HGH dissclved in 0.5 
ml of 0.9% NaCl. The rats were anesthetized 
with ether and frozen by immersion in a hexane-
dry ice bath. One of these rats weighed 54 g 
and was frozen 6 min after injection; the second 
weighed 62 g and was frozen 20 min after in-
jection. 
Whole-body sagittal sections, 20 and 40 f..L 
thick, of the frozen animals were taken on No. 
800 Scotch tape at -15 C. The sections were 
dried and processed for autoradiography by a 
modification (10) of the technique described by 
Ull berg (11) which does not remove or trans-
locate any compounds from the sections. The 
sections were placed against Kodak industrial 
type AA x-ray fihn in individual metal presses. 
Mter development of the autoradiograms, some 
of the sections were stained with hematoxylin 
3 Obtained from Hormone Assay Laboratories, 
Chicago, Ill. 
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and eosin for histological verification of the sitef 
where radioactivity was concentrated. ThE: 
:figures shown were prepared by using the auto-
radiograms as negatives to produce enlargeC 
prints. Consequently, white areas on the print~ 
correspond to radioactivity. The concentratio11 
of radioactivity in the injected tissues was di-
rectly proportional to the degree of whitenesE 
in the prints. Comparisons were usually made 
with blood in the heart since that represents the 
concentration of radioactivity in whole blood. 
Electroplwretic mobility of radioactive materials 
in serum and submandibular glands. To de-
termine how much of the radioactive material 
seen on the autoradiograms might represent 
degraded free iodide, 2 rats, weighing 63 and 
58 g, were injected iv with 2 and 3 ,uCi, re-
spectively, of the same labeled HGH prepara-
tion. They were then anesthetized with ether 
and sacrificed by cardiac exsanguination at 6 
and 20 min, respectively, after the injection. 
The serum was subjected to paper electro-
phoresis as described above except for the 
measurement of the radioactivity, which was 
performed in a Packard gamma spectrometer 
after the paper strips were cut into 1 em seg-
ments. The amount of radioactivity migrating 
as proteill and as free iodide was compared with 
a similar electrophoretogram in which the 
labeled HGH was added in vitro to plasma from 
a control hypox rat. 
The radioactivity appearing in the sub-
mandibular glands was studied by cutting out 
the area containing the submandibular glands 
from five 40 ,., sections taken from the rat killed 
6 min foJ1owing its injection. These tissues were 
applied to the origin of a paper strip and sub-
jected to electrophoresis and evaluated in the 
manner described. 
Accumulation of 12"1-HGH and 131!-HSA in 
organs and effect of pretreatment with ACTH and 
HGH. For direct counting of radioactivity, the 
pancreas, spleen, liver, kidney, adrenals, bone 
(distal end of femur), thymus and subman-
dibular glands were excised, carefully trimmed 
of excess tissues, and weighed on a torsion 
balance. The adrenals, pancreas, right kidney, 
bone, thymus and submandibular glands were 
counted in toto, whereas a weighed representa-
tive portion of the liver was counted. All count-
ing was done in the well of a Packard gamma 
spectrometer. Four groups, each containing 2 
rats, were used. One member of each group was 
killed 6 min after receiving the radiolabeled 
compound and the other member was killed at 
20 min. The groups were treated as follows: 
}roup 1, 2.5 ~Ci "'l-HSA; Group 2, 7 ~Ci 
"I-HGH; Group 3, 0.5 U ACTH followed 6 
nin later by 7 ,uCi 1251-HGH; and Group 4, 
>6 ~g HGH 6 min before 7 ~Ci "'1-HGH. The 
iistribution of radioactivity among the re-
;pective organs at each time interval was cal-
~u]ated as the ratio of radioactivity found per 
ng of tissue to injected dose of radioactivity 
;>er mg of whole rat. In these studies the ac-
~umulation of 1311-HSA was used as a reference 
:;tandard to which the accumulation of 1251-
H:GH was compared. The ratio of the accumu-
.ation of 1251-HGH to the accumulation of 
·"I-HSA was calculated at both time intervals 
~or each organ. 
Results 
The 1251-HGH preparations used were of 
1cceptable purity. No more than 3% of the 
radioactivity migrated as free iodide and 
this was not significantly increased (4%) 
when added in vitro to hypox rat serum. 
Six minutes after the 1251-HGH was in-
jected, free iodide made up 8.6% of the 
total plasma radioactivity and by 20 min-
rrtes this had increased to 22.5%- Because 
of this rapid deiodination, more value 
should be assigned to rats with the shortest 
interval between injection and sacrifice. In 
the submandibular glands, 10.5% of the 
total radioactivity was present in the form 
offree iodide at six minutes. 
Autoradiographic distribution of 12'1-HGH. 
The general patterns of distribution of ra-
dioactivity in the whole-body sections of 
the two rats were quite similar. In the rat 
frozen six minutes after injection, the liver, 
adrenal cortex, submandibular gland, kid-
ney, nasal mucosa and follicles of vibrissae 
were found to have a higher concentration 
of radioactive material than was present in 
the blood (Fig. 1 and 2). Concentration of 
radioactive material in the pancreas (Fig. 2) 
was approximately equal to that of blood. 
In both rats, concentration of radioactivity 
in the thymus was much lower than that 
in blood. In bone, the highest concentration 
of radioactive material was found in the 
cancellous bone in the epiphyses and meta-
physes, while a somewhat lower concentra-
tion was present in the compact bone of 
the diaphyses (Fig. 3). There was no visible 
evidence of accumulation of radioactive 
material along the epiphyseal plates or in 
articular cartilage. 
Fig. 4 is a print of an autoradiogram 
from the rat which was frozen 20 minutes 
after injection. The pattern of distribution 
was the same except for an increased con-
centration of radioactivity within the con-
tents of the stomach. No radioactivity 
could be seen along the epiphyseal plate 
of the humerus (Fig. 5). The lack of ac-
cumulation ofradioactiviLy in the pancreas 
and the higher concentrations in the liver, 
kidney and adrenal cortex in these sections 
are apparent (Fig. 5). 
Fig. 6 is an enlarged print from another 
autoradiogram of the rat frozen 20 minutes 
after injection. This enlargement shows in 
greater detail the radioactivity in the adre-
nal cortex and kidney. Comparison of this 
autoradiogram with the stained section 
from which it was produced revealed that 
the highest concentration of radioactivity 
was in the zona glomerulosa, with decreas-
ing concentrations in the zona fasciculata 
and zona reticularis. Due to the thickness 
of the sections and the tissue damage from 
freezing, it could not be verified histolog-
ically whether the intense radioactivity in 
the kidney was concentrated in the glo-
meruli or proximal tubules. 
Direct counting of excised organs. The ratios 
of the distribution of radioactivity from 
1251-HGH to that of '311-HSA for the eight 
excised organs counted are shown in Table 
1. At both 6 and 20 minutes after injection 
the accumulation of radioactivity from 
1251-HGH was greater than that from 
1311-HSA in adrenals, liver, kidney and sub-
mandibular glands. Radioactivity in the 
pancreas from 1251-HGH was equal to that 
from 1311-HSA at six minutes and higher 
than that from 1311-HSA at 20 minutes. 
The values for 1251-HGH in spleen, thymus 
and bone were lower than those for 1311-
HSA at both time intervals. Pretreatment 
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BLOOD THYMUS BLOOD IN HEART LIVER STOMACH 
FIG. 1. Whole-body autoradiogram of rat killed 6 min following 10 ,uCi of125I-HGH iv. White areas corre-
spond to radioactivity. Compare the concentration in the blood in the heart with that in the submandibu-
lar gland, liver, kidney and adrenal cortex. 
with ACTH increased the accumulation of 
radioactivity from 1251-HGH over that 
from 131J-HSA in adrenals at both time in-
tervals, while these ratios were unchanged 
or slightly lowered in the other organs 
counted. At both 6 and 20 minutes, pre-
treatment with unlabeled HGH greatly de-
creased the ratio of accumulation of radio-
activity from "''1-HGH to that from IHI-
HSA in the liver and adrenals, while this 
ratio was substantially increased in kidney 
and only slightly altered elsewhere. 
Discussion 
In prevwus studies the distribution of 
iodinated or tritiated GH was determined 
by measuring the radioactivity in whole or 
homogenized organs which were removed 
at various times after injection (1-3, 5). 
With such techniques, high concentrations 
in small portions of an organ may be ob-
scured. In other reports selected organs 
were placed in fixing solutions, dehydrated, 
and subjected to routine histological tech-
niques. Autoradiograms were then prepared 
in order to locate the radioactivity within 
the organ studied (2, 4-6). In this study, 
whole-body autoradiograms made from 
freeze-dried, but otherwise untreated, tis-
sues were used to determine whether im-
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portant concentrations of radioactivity had 
been overlooked previously. In addition to 
preventing the removal or translocation 
of labeled compounds within tissues, this 
technique reveals gradients of concentra-
tions within organs and tissues. 
Earlier studies (1, 2, 12) have suggested 
that labeled hormones tend to concentrate 
very quickly in their respective target tis-
sues after administration. Therefore, time 
intervals of 6 and 20 minutes between ad-
ministration of the labeled hormone and 
death of the animals were chosen in this 
study. 
By both the autoradiographic technique 
and the technique of counting excised or-
gans directly, the distribution of radioac-
tivity was found to be similar in rats frozen 
6 and 20 minutes after receiving 125!-HGH. 
The consistent findings in this and in all 
earlier reports (1-6) are higher concentra-
tions of radioactivity in the liver and kid-
ney and the absence of significant concen-
trations of radioactivity in epiphyseal 
cartilages. A striking finding in this study 
was the early concentration of large amounts 
of radioactivity in the adrenal cortices. 
Sonenberg et al. (1, 2) found increased 
levels of radioactivity in the adrenals of 
rats killed ten minutes following intracar-
FIG. 2. Same rat as in Fig. 1. Very little radioactive material is present in the pancreas. Epiphyseal cartilages 
do not concentrate 1251-HGH. Concentrations in epiphysis and diaphysis of femur are slightly higher than 
that of blood. Note activity in follicles of vibrissae. 
dial injections of 131!-bovine GH. Since 
autoradiography was not employed, the 
distribution of radioactivity within the 
gland was not discerned. Radioactivity was 
found to be concentrated primarily in the 
zona reticularis of the adrenal cortices of 
rats, 20 days of age, following ip injections 
of 1251-HGH (6). No activity was demon-
strable in the adrenal cortices of similar 
rats injected with 125!-labeled human lu-
teinizing hormone, bovine serum albumin, 
or "'I-Nal. Autoradiograms from rats in-
jected with 1311-ACTH or histological prep-
arations from rats injected with ACTH 
conjugated with fluorescent dyes revealed 
labeled materials concentrated primarily in 
the inner two layers of the adrenal cortex 
(12, 13). In the present study, the concen-
tration of radioactivity was greatest in the 
zona glomerulosa. 
In addition to the adrenals, liver and 
kidney, the autoradiograms studied here 
revealed localizations of radioactive ma-
terial in the submandibular glands, nasal 
mucosa, gastric mucosa, bone and follicles 
of vibrissae, as judged by autoradiographic 
densities. No other organ or tissue showed 
a higher concentration of radioactivity 
than that present in the blood. The high 
concentrations of radioactivity seen in the 
stomach, nasal mucosa and vibrissae were 
, probably due i o iodide which had been re-
moved from the growth hormone. High 
concentrations in all these areaS are seen 
in whole-body autoradiograms of mice and 
rats injected with 125!-Nai (14). 
Several studies on the distribution of 
serum protein labeled with either radio-
iodine or fluorescent dyes (6, 12, 15) have 
not revealed specific localization in either 
the adrenal cortex or the submandibular 
gland with any of the substances injected. 
Ill 
FIG. 3. Enlargement of area 
containing femur and tibia 
from Fig. 2. The kidney is in 
the upper left corner. Radio-
active materials are restricted 
to bone. There is no detectable 
activity in articular and epi-
physeal cartilages. 
EPIPHYSEAL CARTILAGE TRABECULA 
Mancini (12) found G H which had been 
labeled with either Rhodamine B or fluo-
rescein isothiocyanate in the epiphyseal 
cartilages of rats killed two to three hours 
following iv injection. 
Quantitative determinations of radio-
activity in excised organs were done to 
determine the specificity of the localization 
of ''"I-HGH. It was considered that the 
distribution of '"'I-HSA would serve as a 
nonspecific protein for comparison. It was 
assumed that pretreatment of the animal 
with lar!'e amounts of unlabeled HGH 
would saturate receptor sites and minimize 
the uptake of labeled hormone if radio-
active accumulation was due to the hor-
mone itself and not due to contaminants 
or degradation products. Similarly, pre-
treatment with ACTH was carried out to 
eliminate the possibility that the radio-
active preparation was contaminated with 
ACTH. 
SALIVARY GLAND ADRENAL CORTEX KIDNEY 
THYMUS BLOOD IN HEART LIVER STOMACH 
FIGURE4 
FIG. 4 and 5. Whole-body autoradiograms from rat killed 20 min following 10 ,uCi 1251-HGH iv. Except 
for concentration of activity in gastric mucosa and in contents of stomach, the distribution is similar to 
that of rat killed 6 min following the injection. 
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SPLEEN KIDNEY 
FIGURE 5 
The quantitative determinations of ra-
dioactivity verify the patterns of distribu-
tion seen in the autoradiograms. Since the 
increased concentration of radioactivity in 
the adrenals and kidneys was limited to 
the cortices, the increase in the total counts 
per mg of organ was obscured because of 
the inclusion of the medullary tissue which 
did not have an affinity. This emphasizes 
the usefulness of the autoradiographic 
technique. It is clear from these studies 
that the accumulation of 1251-HGH in the 
adrenals and liver is not due to contamina-
tion of the iodinated solution with 125I-
ACTH since it is blocked by the prior ad-
ministration of unlabeled HGH. The rea-
son for the surprising enhancement of the 
accumulation of 1251-HGH by the adrenals 
after pretreatment with ACTH is not en-
tirely clear, but one of us ( JJVW) has 
observed large increases in the adrenal 
blood flow in dogs after the administration 
of ACTH intravenously. The enhanced 
accumulation of 1251-HGH by the kidney 
after pretreatment with HGH has no clear 
explanation but conceivably might result 
from the saturation of tubular reabsorption 
sites. The finding that pretreatment with 
unlabeled HGH failed to suppress uptake 
of 1251-HGH in the submandibular glands 
is confusing in view of the autoradio-
graphic and electrophoretic findings. 
Although it is not possible to infer a spe-
cific physiologic significance from the fact 
that growth hormone is rapidly concen-
trated in a given organ, such a finding may 
provide clues regarding the organs in which 
secondary growth factors are formed. The 
possibility that growth hormone is concen-
trated in the submandibular gland is par-
ticularly intriguing since a potent nerve 
growth factor and an epithelial growth 
factor have been extracted from subman-
dibular glands of mice (16, 17). Further-
more, several mammals, including the rat, 
have been reported to respond to sub-
!13 
mandibular adenectomy with a drastically 
reduced rate of linear growth (18). Neither 
loss of exocrine function nor anorexia due 
to dysphagia was apparently responsible 
for this growth arrest. The relevance, if 
any, of these observations to the early con-
centration of growth hormone in the sub-
mandibular gland remains to be explored. 
Growth hormone has been reported to 
increase adrenal weight and increase the 
width of the zona reticularis (19). Recent 
evidence suggests that GH plays a signif-
icant role in the release of aldosterone from 
the adrenals of chronically salt restricted, 
hypox rats (20). 
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FIG. 6. Distribution of radio-
active material in the kidney 
and adrenal cortex (same rat 
as in Fig. 4 and 5). The 
gradient of concentration of 
activity in the adrenal cortex 
appears to be greatest in the 
zona glomerulosa and least in 
the zona reticularis. No ac-
tivity is present in the me-
dulla. Activity in kidney is re-
stricted to renal cortex. 
Aldosterone release can be demonstrated 
with adrenals from intact rats during in 
vitro incubation but not with adrenals from 
hypox rats (21). Adrenals from hypox rats 
regained their ability to secrete aldosterone 
after treatment with monkey GH. Further-
more, serum from such GH-treated an-
imals, but not GH itself, increased aldos-
terone release in vitro from adrenals of 
intact rats (21). 
These observations on GH and aldos-
terone secretion complement the discovery 
that GH does not act directly to stimulate 
cartilage growth in vitro (7, 8). Since radio-
activity does not accumulate in the epi-
TABLE 1. mr.HGH distribution/1311-HSA distribution 
Pretreatment 
Organ 
None ACTH HGH 
Spleen 0.56 0.57 0.55 
Pancreas 1.03 0.79 0.98 
Kidney 3.37 2.94 5.50 
Liver 1.51 1.44 0. 72 
6 min after 1251-HGH Adrenals 1.31 2.96 0.73 
Bone 0.46 0.46 0.54 
Thymus 0.35 0.38 0.44 
Submandibular glands 1. 77 1.39 1.59 
Spleen 0.58 0.63 0.59 
Pancreas 1.43 1.29 1.29 
Kidney 1.90 2.06 3.37 
Liver 2 .30 2.37 0.72 
20 mi.n after 1 ~51-HGH Adrenals 1 .34 3.01 0.55 
Bone 0 .47 0.41 0.45 
Thymus 0 .89 0.78 1.28 
Submandibular glands 1 .79 1.65 1.27 
----
Values are the ratio of the distribution of 1201-HGH to the distribution of 1·111-HSA at each of 2 time 
intervals after injection of labeled material. The distribution of radioactivity was calculated as the ratio 
of the radioactivity found per mg of tissue to the radioactivity administered per mg of whole animal. 
Nonlabeled ACTH or HGH was given 6 min prior to the mr-HGH. 
physeal cartilage following the injection of 
tritiated or iodinated GH in vivo (2, 4-6), 
the concentrations of radioactivity in the 
zona glomerulosa of adrenals from rats 
studied here suggest that separate path-
ways or mechanisms could exist through 
which GH exerts its influence on these 
diverse functions. 
These studies provide some "meager clues 
regarding the site of origin of the growth 
hormone-dependent sulfation and thymi-
dine factors which promote growth in 
skeletal tiseue. The possibility that either 
the submandibular glands or the adrenals 
may be required for the formation of growth 
hormone-dependent skeletal growth factors 
is being investigated and will be reported 
subsequently. 
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Somatomedin: Proposed Designation for Sulphation Factor 
The action of growth hormone (GH) on skeletal tissue was proposed to be mediated 
through a secondary substance, described by the operational term 'sulphation factor".' 
The observations underlying this hypothesis have been amply confirmed and extended. A 
GH-dependent plasma factor stimulates in cartilage not only the incorporation of sul-
phate into chondroitin sulphate, but also the incorporation of thymidine into DNA2 , 
proline into the hydroxyproline of collagen' and uridine into RNA4 • GH has substan-, 
tially no in vitro effect on cartilage metabolism. 
In plasma sulphation factor (SF) circulates associated with the large molecular com-
ponents but extracts of considerably smaller size with sulphation factor activity have 
been prepared by denaturating plasma protein by boiling4 or by extraction with acid 
ethanol.' Van Wyk et al 5 purified their acid ethanol extracts by gel filtration, ion 
exchange chromatography and electrophoresis. After an approximate 25,000-fold purifi-
cation, the biological activity could be attributed to a neutral peptide with a molecular 
weight of about 8,000 (ref. 6). 
The spectrum of biological action of SF has been extended by experiments with partially 
purified SF. Hall and Uthne7 demonstrated that injections of SF active extracts induced 
widening of the tibial epiphyseal cartilage. The biological actions of SF are not limited to 
cartilage. Salmon and Du Vall8 showed that partially purified SF had insulin-like actions 
on isolated rat diaphragm and Hall and Uthne 7 have shown that similar SF preparations 
stimulate conversion of 14 C-glucose to 14 C02 by rat adipose tissue. The insulin-like 
activity cannot be neutralized by anti-insulin serum and follows SF activity through 
multiple fractionation procedures5 , suggesting that SF is identical with or very similar to 
the smaller molecular weight component of the non-suppressible insulin-like activity 
(NSILA-S) extensively studied by Jakob, Hauri and Froesch9 NSILA-S stimulates 
thymidine incorporation in rat costal cartilage. 1 0 Recently Salmon and Hosse 11 reported 
that a serum fraction with SF activity stimulated HeLa cell growth. 
Although the mechanism of production and ultimate physiological role of SF remain to 
be defined, its importance in the growth and anabolic responses of both skeletal and 
certain non-skeletal tissues can be in no doubt. After consideration of many alternatives to 
the operational terms 'sulphation factor' or 'thymidine factor', we propose the more 
general term, 'somatomedin'; the prefix, 'somata', connotes both a hormonal relationship 
to somatotropin and, also, to the soma which is the target tissue of this agent. 'Medin' is 
included in the name to indicate that it is an intermediary in somatotropin action. 
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